Paula

```
=> d his ful
     FILE 'HCAPLUS' ENTERED AT 15:40:00 ON 30 JAN 2007
                E 180916-16-9/RN
L1            1 SEA ABB=ON  PLU=ON  180916-16-9/RN
                D STAT QUE L1
                D IDE CAN L1

     FILE 'HCAPLUS' ENTERED AT 15:41:36 ON 30 JAN 2007

     FILE 'REGISTRY' ENTERED AT 15:42:20 ON 30 JAN 2007
                SET SMARTSELECT ON
L2              SEL PLU=ON  L1 1- CHEM :       2 TERMS
                SET SMARTSELECT OFF

     FILE 'HCAPLUS' ENTERED AT 15:42:21 ON 30 JAN 2007
L3          136 SEA ABB=ON  PLU=ON  L2
L4            0 SEA ABB=ON  PLU=ON  L3 AND (INFLAMMATORY(W)BOWEL OR IBD)
                D STAT QUE L4
L5       260272 SEA ABB=ON  PLU=ON  ("INFLAMMATORY BOWEL DISEASE"/CV OR
                "INTESTINE, DISEASE (L) INFLAMMATORY"/CV) OR BOWEL OR INTESTIN?
L6           16 SEA ABB=ON  PLU=ON  L3 AND L5
L7            1 SEA ABB=ON  PLU=ON  L3(L)?INFLAMM?
L8           17 SEA ABB=ON  PLU=ON  L6 OR L7
                D STAT QUE L8
                D IBIB ABS HITSTR L8 1-17
L12         262 SEA ABB=ON  PLU=ON  ("MACLEAN DAVID"/AU OR "MACLEAN DAVID
                A"/AU OR "MACLEAN DAVID B"/AU OR "MACLEAN DAVID BAILEY"/AU OR
                "MACLEAN DAVID BARKER"/AU OR "MACLEAN DAVID BURTON"/AU) OR
                MACLEAN D/AU OR MACLEAN D B/AU
L13         421 SEA ABB=ON  PLU=ON  THOMPSON D/AU OR THOMPSON D D/AU OR
                "THOMPSON DAVID"/AU OR ("THOMPSON DAVID D"/AU OR "THOMPSON
                DAVID DUANE"/AU)
L14          20 SEA ABB=ON  PLU=ON  L12 AND L13
L15          25 SEA ABB=ON  PLU=ON  (L12 OR L13) AND L3
L16          11 SEA ABB=ON  PLU=ON  (L12 OR L13) AND L5
L17          49 SEA ABB=ON  PLU=ON  L14 OR L15 OR L16
L18          46 SEA ABB=ON  PLU=ON  L17 NOT L8
                D STAT QUE L18
                D IBIB ABS HITSTR L18 1-46


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   29 JAN 2007  HIGHEST RN 918776-45-1
     DICTIONARY FILE UPDATES:  29 JAN 2007  HIGHEST RN 918776-45-1

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:41:12 ON 30 JAN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1
DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
=>

=> => d stat que l1

```
L1             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  180916-16-9/RN


=> d ide can l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   180916-16-9  REGISTRY
ED   Entered STN:  18 Sep 1996
CN   2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-
     pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-
     pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-
OTHER NAMES:
CN   Lasofoxifene
FS   STEREOSEARCH
MF   C28 H31 N O2
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU,
       DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, PROUSDDR,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.  Rotation (-).
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             122 REFERENCES IN FILE CA (1907 TO DATE)
               7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             122 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  146:74355

REFERENCE   2:  146:19295

REFERENCE   3:  145:483657

REFERENCE   4:  145:465947
```

```
REFERENCE   5:  145:262315

REFERENCE   6:  145:240583

REFERENCE   7:  145:225326

REFERENCE   8:  145:20362

REFERENCE   9:  145:944

REFERENCE  10:  145:252


=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:41:36 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007  VOL 146 ISS 6
FILE LAST UPDATED: 29 Jan 2007  (20070129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> => d stat que l4
L1             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  180916-16-9/RN
L2               SEL  PLU=ON  L1 1- CHEM :       2 TERMS
L3           136 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L4             0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND (INFLAMMATORY(W)BOWEL
                 OR IBD)


=>
=> d stat que l8
L1             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  180916-16-9/RN
L2               SEL  PLU=ON  L1 1- CHEM :       2 TERMS
L3           136 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L5        260272 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("INFLAMMATORY BOWEL DISEASE"/
                 CV OR "INTESTINE, DISEASE (L) INFLAMMATORY"/CV) OR BOWEL OR
                 INTESTIN?
L6            16 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L5
L7             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L)?INFLAMM?
L8            17 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 OR L7
```

=> d ibib abs hitstr l8 1-17

L8 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:971035 HCAPLUS Full-text
DOCUMENT NUMBER: 146:74355
TITLE: Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis
AUTHOR(S): Gennari, Luigi
CORPORATE SOURCE: Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Policlinico Le Scotte, University of Siena, Siena, Italy
SOURCE: Drugs of Today (2006), 42(6), 355-367
CODEN: MDACAP; ISSN: 1699-3993
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Selective estrogen receptor modulators (SERMs) are structurally different compds. that interact with intracellular estrogen receptors in target organs as estrogen agonists and antagonists. Thus far SERMs have proven to be a highly versatile group and are being evaluated primarily for conditions associated with aging, including hormone-responsive cancer and osteoporosis. Tamoxifen and toremifene are currently used to treat advanced breast cancer and also have beneficial effects on bone mineral d. and serum lipids in post-menopausal women. Raloxifene is the only SERM compound actually approved worldwide for the prevention and treatment of postmenopausal osteoporosis and fragility fractures. Unfortunately, although these SERMs possess many benefits, they are also responsible for some very serious side effects, such as thromboembolic disorders and, in the case of tamoxifen, uterine cancer. These contraindications represent a major concern for the type of long-term, chronic therapy that is required to prevent osteoporosis. Moreover, both preclin. and clin. reports suggest that these SERMs are considerably less potent than estrogen, probably due to their reduced bioavailability. Lasofoxifene (CP 336,156) is a naphthalene-derivative, third-generation SERM, structurally distinct from the first- and second-generation SERMs. This compound selectively binds to both estrogen receptor subtypes (estrogen receptor-alpha or -beta) with high affinity. It has a half-inhibition concentration similar to that seen with estradiol and thus at least 10-fold higher than those reported for raloxifene and tamoxifen. Moreover, due to increased resistance to intestinal wall glucuronidation, lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs. In both preclin. and short-term clin. studies lasofoxifene has shown a proven efficacy in preventing bone loss and lowering cholesterol levels. Dose modeling from phase II studies allowed the selection of lasofoxifene 0.25 mg/day as the lowest fully ED. The compound shows a favorable safety profile and is currently in phase III development for the prevention and treatment of osteoporosis in post-menopausal women.

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene was safe and effective for treatment of osteoporosis in postmenopausal woman)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:818823 HCAPLUS Full-text
DOCUMENT NUMBER: 145:262315
TITLE: Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis
AUTHOR(S): Gennari, Luigi; Merlotti, Daniela; Martini, Giuseppe; Nuti, Ranuccio
CORPORATE SOURCE: University of Siena, Endocrine-Metabolic Sciences and Biochemistry, Department of Internal Medicine, Siena, 53100, Italy
SOURCE: Expert Opinion on Investigational Drugs (2006), 15(9), 1091-1103
CODEN: EOIDER; ISSN: 1354-3784
PUBLISHER: Informa Healthcare
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. This article reviews lasofoxifene, a new-generation selective estrogen receptor modulator (SERM) that is currently in Phase III development for the prevention and treatment of osteoporosis in postmenopausal women. This compound selectively binds to both of the estrogen receptors with a high affinity and a median inhibitory concentration that is similar to that seen with estradiol and ≥ 10-fold higher than those reported for other SERMs (raloxifene and tamoxifen). Lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs due to increased resistance to intestinal wall glucuronidation. In both preclin. and short-term studies, the compound showed a favorable safety profile and demonstrated a proven efficacy in preventing bone loss and lowering cholesterol levels. Dose modeling from Phase II studies allowed the selection of lasofoxifene 0.25 mg/day as the lowest fully ED.

IT 180916-16-9, Lasofoxifene
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene, a third-generation selective estrogen receptor modulator for prevention and treatment of osteoporosis)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1354726 HCAPLUS Full-text
DOCUMENT NUMBER: 144:81225
TITLE: 5-LOX inhibitors and bone and cartilage beneficial agent combinations for arthritis, osteoporosis, or pain
INVENTOR(S): Christgau, Stephan; Hansen, Christian; Nilsson, Henrik
PATENT ASSIGNEE(S): Osteologix A/S, Den.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123130	A2	20051229	WO 2005-DK403	20050617
WO 2005123130	A3	20060202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DK 2004-948 A 20040617

AB Combination treatments, wherein a 5-lipoxygenase (5-LOX) inhibitor are administered together with a bone or cartilage beneficial compound in order to obtain a therapeutically beneficial effect in the treatment and/or prophylaxis of osteoarthritis, rheumatoid arthritis, osteoporosis or pain, and pharmaceutical compns. comprising a combination of a 5-LOX inhibitor and a bone and cartilage beneficial compound

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-LOX inhibitor and bone and cartilage beneficial agent combinations for arthritis, osteoporosis, or pain)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1239173 HCAPLUS Full-text

DOCUMENT NUMBER: 143:477963

TITLE: Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer

INVENTOR(S): Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum

PATENT ASSIGNEE(S): Bayer Pharmacueticals Corporation, USA

SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110994	A2	20051124	WO 2005-US15106	20050502
WO 2005110994	A3	20060202		
WO 2005110994	A8	20061221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

CA 2564325 A1 20051124 CA 2005-2564325 20050502
PRIORITY APPLN. INFO.: US 2004-566445P P 20040430
WO 2005-US15106 W 20050502

OTHER SOURCE(S): MARPAT 143:477963
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-2 = H, alkyl, halo; A = Ph, pyridine, pyrimidine; B = phenylene, naphthylene; L = O, S, CH2; M = Ph, pyridine, pyrimidine; n = 0-1; X = O, SO2, etc.; Y = alkoxy, oxycarbonyl, amino, etc.] are prepared For instance, II is prepared from 4-[3-tert-butyl-5-[N'-[4-(pyridin-4-yloxy)phenyl]ureido]pyrazol-1-yl]benzoic acid Me ester (preparation given) and 2-(pyrrolidin-1-yl)ethylamine (DCE, AlMe3, 80°, 16 h). Compds. of the invention show significant inhibition of TrkA kinase (IC50 < 1 μM). I are useful for the treatment of cancer.

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted pyrazolylurea derivs. useful for cancer treatment)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:490384 HCAPLUS Full-text
DOCUMENT NUMBER: 143:42681
TITLE: Anti-IGFR-1 antibodies in combination with chemotherapeutic agent for treating cancer
INVENTOR(S): Wang, Yan; Pachter, Jonathan A.; Bishop, Walter R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005052005	A1	20050609	WO 2004-US38842	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004292554	A1	20050609	AU 2004-292554	20041119
CA 2546664	A1	20050609	CA 2004-2546664	20041119
US 2005136063	A1	20050623	US 2004-993395	20041119
EP 1689782	A1	20060816	EP 2004-811545	20041119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
NO 2006002885	A	20060818	NO 2006-2885	20060620
PRIORITY APPLN. INFO.:			US 2003-524732P P	20031121
			WO 2004-US38842 W	20041119

AB The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. The antibody is e.g. a human monoclonal antibody recognizing human IGFR-1, especially soluble IGFR-1. The chemotherapeutic agent is selected from a taxane, topoisomerase inhibitor, signal transduction inhibitor, cell cycle inhibitor, farnesyl protein transferase inhibitor, EGFR inhibitor, HER2 inhibitor, VEGFR inhibitor, MAP kinase inhibitor, MEK kinase inhibitor, AKT kinase inhibitor, mTOR inhibitor, etc. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

IT 180916-16-9, Lasofoxifene
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-IGFR-1 antibodies in combination with chemotherapeutic agent for treating cancer)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:470251 HCAPLUS Full-text
DOCUMENT NUMBER: 143:19957
TITLE: Combination therapy comprising a cyclooxygenase 2 (COX-2) inhibitor and an antineoplastic agent for treatment or prevention of neoplasia
INVENTOR(S): Masferrer, Jaime L.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048942	A2	20050602	WO 2004-US38019	20041115
WO 2005048942	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005227929	A1	20051013	US 2004-989192	20041115
PRIORITY APPLN. INFO.:			US 2003-519701P	P 20031113

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a COX-2 inhibitor and an antineoplastic agent.

IT 180916-16-9, Lasofoxifene
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(cyclooxygenase 2 inhibitor-antineoplastic agent combination for treatment or prevention of neoplasia)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:995989 HCAPLUS Full-text

DOCUMENT NUMBER: 142:747

TITLE: Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

INVENTOR(S): Hansen, Christian; Nilsson, Henrik

PATENT ASSIGNEE(S): Nordic Bone A/S, Den.; Osteologix A/S; Christgau, Stephan

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098618	A2	20041118	WO 2004-DK327	20040506
WO 2004098618	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004237438	A1	20041118	AU 2004-237438	20040506

CA 2524610		A1	20041118	CA 2004-2524610	20040506
EP 1622630		A2	20060208	EP 2004-731315	20040506
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006525242		T	20061109	JP 2006-504378	20040506
EP 1745791		A2	20070124	EP 2006-21612	20040506
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
AU 2005240257		A1	20051117	AU 2005-240257	20050505
CA 2565840		A1	20051117	CA 2005-2565840	20050505
WO 2005108339		A2	20051117	WO 2005-DK307	20050505
WO 2005108339		A3	20051229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1744770		A2	20070124	EP 2005-734804	20050505
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006275503		A1	20061207	US 2006-556149	20060720
PRIORITY APPLN. INFO.:				DK 2003-691	A 20030507
				DK 2003-931	A 20030620
				DK 2003-1819	A 20031209
				US 2003-528548P	P 20031209
				DK 2003-932	A 20030620
				DK 2003-1820	A 20031209
				US 2003-528442P	P 20031209
				EP 2004-731317	A3 20040506
				WO 2004-DK326	W 20040506
				WO 2004-DK327	W 20040506
				WO 2004-DK328	W 20040506
				DK 2004-1708	A 20041105
				WO 2005-DK307	W 20050505

AB A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone d. and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination treatment with strontium for prophylaxis and/or treatment of cartilage and/or bone conditions)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:759835 HCAPLUS Full-text
DOCUMENT NUMBER: 141:277616
TITLE: Preparation of 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as nep inhibitors
INVENTOR(S): Hepworth, David
PATENT ASSIGNEE(S): Pfizer Inc., UK
SOURCE: U.S. Pat. Appl. Publ., 27 pp., which
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180941	A1	20040916	US 2004-800065	20040312
AU 2004220269	A1	20040923	AU 2004-220269	20040309
CA 2519072	A1	20040923	CA 2004-2519072	20040309
WO 2004080985	A1	20040923	WO 2004-IB822	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1606272	A1	20051221	EP 2004-718706	20040309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008377	A	20060321	BR 2004-8377	20040309
CN 1761656	A	20060419	CN 2004-80006939	20040309
JP 2006526572	T	20061124	JP 2006-500337	20040309
NL 1025709	A1	20040916	NL 2004-1025709	20040312
NL 1025709	C2	20050314		

NO 2005004169	A	20051207	NO 2005-4169		20050907
PRIORITY APPLN. INFO.:			GB 2003-5916	A	20030314
			US 2003-464608P	P	20030422
			GB 2003-29143	A	20031216
			US 2004-538079P	P	20040120
			WO 2004-IB822	A	20040309

OTHER SOURCE(S): MARPAT 141:277616

GI



I



II

AB The invention relates to the use of title compds. I [R1 = H or Me; R2 = Me or Et; n = 1 or 2] as inhibitors of neutral endopeptidase enzyme (NEP), processes for the preparation thereof, intermediates used in the preparation thereof and compns. containing said inhibitors. Thus, e.g., II was prepared by amidation of 1-[(2R)-3-tert-butoxy-2-methyl-3-oxopropyl]cyclopentane carboxylic acid with 3-(2-methyl-1,3-benzothiazol-6-yl)propylamine dihydrochloride (preparation given) with subsequent hydrolysis to provide the free acid. I have been demonstrated to possess IC50 values of <20 nanomolar in tests for NEP inhibition and demonstrate a selectivity over soluble secreted endopeptidase (SEP) of at least 1000 fold. These inhibitors have utility in a variety of therapeutic areas including the treatment of male and female sexual dysfunction, particularly female sexual dysfunction (FSD), especially wherein the FSD is female sexual arousal disorder (FSAD).

IT 180916-16-9, Lasofoxifene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of ([(benzothiazolyl)propylcarbamoyl]cycloalkyl)propanoic acid derivs. as inhibitors of neutral endopeptidase enzyme)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:756710 HCAPLUS Full-text
DOCUMENT NUMBER: 141:277628
TITLE: Preparation of ureidophenoxycyanopyridines as anticancer drugs.
INVENTOR(S): Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078747	A1	20040916	WO 2004-US6286	20040301
WO 2004078747	A8	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004235829	A1	20041125	US 2004-788029	20040227
AU 2004217977	A1	20040916	AU 2004-217977	20040301
CA 2517361	A1	20040916	CA 2004-2517361	20040301
US 2004229937	A1	20041118	US 2004-789446	20040301
US 2005032798	A1	20050210	US 2004-788405	20040301
US 2005038031	A1	20050217	US 2004-788426	20040301
EP 1599467	A1	20051130	EP 2004-716144	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007897	A	20060301	BR 2004-7897	20040301

JP 2006519264	T	20060824	JP 2006-508977		20040301
CN 1839126	A	20060927	CN 2004-80011547		20040301
PRIORITY APPLN. INFO.:			US 2003-450323P	P	20030228
			US 2003-450324P	P	20030228
			US 2003-450348P	P	20030228
			WO 2004-US6286	A	20040301

OTHER SOURCE(S): MARPAT 141:277628

GI



I



II

AB Title compds. [I; A = (substituted) pyridinyl, naphthyl, 8-10 membered bicyclic heteroaryl, heterocyclyl, carbocyclyl; B = (substituted) phenylene, naphthylenediyl; L = O, S; m = 0-3; R2 = alkyl, haloalkyl, alkoxy, N-oxo, N-hydroxy], were prepared Thus, 2-trifluoromethyl-4- pyridylamine was stirred 20 h with carbonyldiimidazole in CH2Cl2; 4-(4-amino-3-fluorophenoxy)pyridine-2-carbonitrile (preparation given) was added followed by stirring for 1 day to give 75% title compound (II). I inhibited c-RAF-1 kinase with IC50 = 7.86 nM to >1600 nM.

IT 180916-16-9, Lasofoxifene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606368 HCAPLUS Full-text
DOCUMENT NUMBER: 141:134076
TITLE: The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
INVENTOR(S): Elloso, M. Merle; Mitchell, Robert; Harnish, Douglas C.; Adelman, Steven J.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004062653	A2	20040729	WO 2004-US37		20040105
WO 2004062653	A3	20041104			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ					
AU 2004204675	A1	20040729	AU 2004-204675		20040105
CA 2512021	A1	20040729	CA 2004-2512021		20040105
US 2004167112	A1	20040826	US 2004-751543		20040105
EP 1585507	A2	20051019	EP 2004-700191		20040105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2004006643	A	20051206	BR 2004-6643		20040105
CN 1723013	A	20060118	CN 2004-80001876		20040105
JP 2006515616	T	20060601	JP 2006-500772		20040105
NO 2005003156	A	20050908	NO 2005-3156		20050628
PRIORITY APPLN. INFO.:			US 2003-438123P	P	20030106
			WO 2004-US37	W	20040105

AB The present invention provides methods of treating an autoimmune pathol. in a mammal, comprising administering an agent with estrogen receptor-α agonist activity in particular a selective estrogen receptor modulator, to the mammal in an amount sufficient to decrease production of TH-1 and/or TH-2 cytokines. Also provided is a method of selecting compds. useful for the treatment of multiple sclerosis, comprising selecting a compound which has estrogen receptor-α agonist activity.

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of estrogen receptor alpha modulators for the treatment of multiple sclerosis)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:2847 HCAPLUS Full-text
DOCUMENT NUMBER: 140:71530
TITLE: Use of cyclothiocarbamate derivatives as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions
INVENTOR(S): Fensome, Andrew; Grubb, Gary; Harrison, Diane Deborah; Winneker, Richard Craig; Zhang, Puwen; Kern, Jeffrey Curtis; Terefenko, Eugene Anthony
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000801	A2	20031231	WO 2003-US19751	20030623
WO 2004000801	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489847	A1	20031231	CA 2003-2489847	20030623
AU 2003247608	A1	20040106	AU 2003-247608	20030623
US 2004006060	A1	20040108	US 2003-601481	20030623
BR 2003012024	A	20050322	BR 2003-12024	20030623
EP 1515725	A2	20050323	EP 2003-761263	20030623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662241	A	20050831	CN 2003-814681	20030623

JP 2005535624	T	20051124	JP 2004-516143		20030623
NO 2004005216	A	20050124	NO 2004-5216		20041129
PRIORITY APPLN. INFO.:			US 2002-391871P	P	20020625
			WO 2003-US19751	W	20030623

OTHER SOURCE(S): MARPAT 140:71530

GI



I II III

AB The present invention provides methods of inducing contraception which includes delivering to a female a composition containing cyclothiocarbamates (shown as I and II; variables defined below; e.g. III) or tautomers thereof, in a regimen which involves delivering ≥1 of a selective estrogen receptor modulator. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering I or II and a selective estrogen receptor modulator are also described. III (5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6- yl)-1-methyl-1H-pyrrole-2-carbonitrile) showed significant antagonistic activity towards androgens in L929 cells over a nine point dose response (IC50 = 109 nM) and only marginal agonistic activity at the maximum concentration tested (i.e., 10 nM). Although neither I nor II nor the methods of preparation are claimed, 6 example prepns. are included. For example, 1-methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6- yl]-1H-pyrrole-2-carbonitrile was prepared in 5 steps (32, 58, 52, 79, and 49 % yields, resp.) starting from phenylcarbamic acid tert-Bu ester, cyclobutanone and tBuLi in Et2O and involving intermediates tert-Bu [2-(1-hydroxycyclobutyl)phenyl]carbamate, spiro[3,1-benzoxazine-4,1'- cyclobutan]-2(1H)-one, 6-bromospiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)- one, and 1-methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'- cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile. For I: R1 and R2 = H, (un)substituted C1 to C6 alkyl, (un)substituted C2-C6 alkenyl, (un)substituted C2-C6 alkynyl, (un)substituted C3-C8 cycloalkyl, (un)substituted aryl, (un)substituted C-based heterocyclic ring having in its backbone 1-3 heteroatoms, CORA, and NRBCORA; or R1 and R2 are fused to form a ring (a), (b) and (c), wherein said ring is (un)substituted by 1-3 substituents H and C1 to C3 alkyl ((a) a C-based 3 to 8 membered saturated spirocyclic ring; (b) a C-based 3 to 8 membered spirocyclic ring having ≥1 C-C double bonds; and (c) a 3 to 8 membered spirocyclic ring having in its backbone 1-3 heteroatoms O, S and N). R3 = H, OH, NH2, (un)substituted C1 to C6 alkyl, (un)substituted C3-C6 alkenyl, (un)substituted alkynyl, and CORC; R4 = H, halogen, CN, NO2, (un)substituted C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 aminoalkyl; R5 = an X/Y/Z-substituted Ph or a five or six membered C-based heterocyclic ring having in its backbone 1-3 heteroatoms O, S, SO, SO2, and NR6 and having one or two independent

substituents H, halogen, CN, NO2, (un)substituted C1 to C4 alkyl, (un)substituted C1 to C3 alkoxy, (un)substituted C1 to C3 aminoalkyl, (un)substituted C1 to C3 perfluoroalkyl, (un)substituted 5 or 6 membered C-based heterocyclic ring having in its backbone 1-3 heteroatoms, (un)substituted C1 to C3 thioalkyl, CORF, and NRGCORF; Q1 = S, NR7, and CR8R9; addnl. details are given in the claims. For II: R1' = Me, Et, trifluoromethyl; R2' = Me, Et, trifluoromethyl; or R1' and R2' are joined to form a spirocyclic ring containing 3 to 7 C atoms; and R3 =C1 to C4 alkyl; other variables are as for I.

IT 180916-16-9, Lasofoxifene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulator as codrug; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:239231 HCAPLUS Full-text

DOCUMENT NUMBER: 139:143104

TITLE: Novel therapies for osteoporosis

AUTHOR(S): Biskobing, Diane M.

CORPORATE SOURCE: Virginia Commonwealth University/Medical College of Virginia, Richmond, VA, USA

SOURCE: Expert Opinion on Investigational Drugs (2003), 12(4), 611-621
CODEN: EOIDER; ISSN: 1354-3784

PUBLISHER: Ashley Publications Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Osteoporosis remains a significant clin. problem despite effective therapies. Many patients cannot or will not take currently available therapies. For this reason, research continues in search of more effective and more tolerable agents. Anabolic agents offer an unique mechanism of action. The anabolic agents parathyroid hormone and strontium are discussed. The investigational bisphosphonates Ibandronate, Minodronate, and Zoledronic

acid may offer the advantage of less frequent dosing. Arzoxifene, Bazedoxifene, Lasofoxifene, MDL-103,323, and Ospemifene are investigational selective estrogen receptor modulators shown to be effective in animal studies and are now in clin. studies. Tibolone is a tissue-specific steroid that is currently used in Europe for the prevention and treatment of osteoporosis. Multiple studies have shown efficacy in improving bone mineral d., but no fracture studies have been conducted to date. While studies of the effect of isoflavones on bone mineral d. have been encouraging, a large, multicenter study in Europe showed no effect of isoflavones on fractures. The newly described agent Osteoprotegerin has been shown in early studies to inhibit bone turnover. Other agents with unique mechanisms of action in early development include cathepsin K inhibitors, integrin receptor inhibitors, nitrosylated nonsteroidal anti-inflammatory agents, and Src inhibitors. The efficacy of statins in bone continues to be debated with no prospective, randomized studies yet to confirm the suggestion of benefit seen in epidemiol. studies.

REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:391522 HCAPLUS Full-text
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
WO 2002040008	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2429106	A1	20020523	CA 2001-2429106		20011114
AU 200223802	A	20020527	AU 2002-23802		20011114
EP 1333824	A2	20030813	EP 2001-994552		20011114
EP 1333824	B1	20050907			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015364	A	20030923	BR 2001-15364		20011114
HU 200301892	A2	20031128	HU 2003-1892		20011114
JP 2004522710	T	20040729	JP 2002-542382		20011114
NZ 525415	A	20041126	NZ 2001-525415		20011114
AT 303804	T	20050915	AT 2001-994552		20011114
US 2004087561	A1	20040506	US 2003-416934		20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W	20001117
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504
			WO 2001-GB5018	W	20011114

OTHER SOURCE(S): MARPAT 136:395983

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase inhibitors, and lasofoxifene. Preparation of compds. of the invention is described.

L8 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:314394 HCAPLUS Full-text

DOCUMENT NUMBER: 136:335264

TITLE: Use of an estrogen agonists and antagonists for assessment, improvement, or maintenance of urogenital health

INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199069	A2	20020424	EP 2001-308625	20011009
EP 1199069	A3	20031119		
EP 1199069	B1	20061004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 341313	T	20061015	AT 2001-308625	20011009
CA 2358938	A1	20020416	CA 2001-2358938	20011012
CA 2358938	C	20060808		
CA 2541348	A1	20020416	CA 2001-2541348	20011012
US 2002128276	A1	20020912	US 2001-976825	20011012
JP 2002179593	A	20020626	JP 2001-316248	20011015
HU 200104300	A2	20020828	HU 2001-4300	20011015
ZA 2001008443	A	20030415	ZA 2001-8443	20011015
NZ 514821	A	20040130	NZ 2001-514821	20011015

AU 783821	B2	20051208	AU 2001-79412		20011015
US 2003125319	A1	20030703	US 2002-292203		20021112
US 2005215592	A1	20050929	US 2005-137830		20050524
PRIORITY APPLN. INFO.:			US 2000-240789P	P	20001016
			CA 2001-2358938	A3	20011012
			US 2001-976825	A3	20011012
			US 2002-292203	A1	20021112

OTHER SOURCE(S): MARPAT 136:335264

AB The invention relates to methods and kits useful for the improvement, or maintenance urogenital health using an estrogen agonist/antagonist compds. (Markush structures are included). The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

IT 180916-16-9
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of estrogen agonists and antagonists for assessment, improvement, or maintenance of urogenital health)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2001:762983 HCAPLUS Full-text
DOCUMENT NUMBER:	135:303769
TITLE:	Preparation of estrogen agonist/antagonist metabolites
INVENTOR(S):	Day, Wesley Warren; Johnson, Kim Anne; Prakash, Chandra Aggarwal; Eggler, James Frederick
PATENT ASSIGNEE(S):	Pfizer Products Inc., USA
SOURCE:	PCT Int. Appl., 80 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001077093	A1	20011018	WO 2001-IB427		20010319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2405070	A1	20011018	CA 2001-2405070		20010319
EP 1268453	A1	20030102	EP 2001-912069		20010319
EP 1268453	B1	20060719			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001009838	A	20030121	BR 2001-9838		20010319
HU 200300419	A2	20030628	HU 2003-419		20010319
NZ 521291	A	20040227	NZ 2001-521291		20010319
JP 2004510693	T	20040408	JP 2001-575567		20010319
EE 200200580	A	20040615	EE 2002-580		20010319
AT 333450	T	20060815	AT 2001-912069		20010319
US 2002042443	A1	20020411	US 2001-825980		20010404
US 6455572	B2	20020924			
IN 2002DN00888	A	20050121	IN 2002-DN888		20020912
BG 107137	A	20030530	BG 2002-107137		20020923
NO 2002004767	A	20021203	NO 2002-4767		20021003
ZA 2002007995	A	20031020	ZA 2002-7995		20021004
US 39419	E1	20061205	US 2003-448751		20030530
HK 1052511	A1	20050930	HK 2003-104866		20030708
PRIORITY APPLN. INFO.:			US 2000-267198P	P	20000407
			WO 2001-IB427	W	20010319
			US 2001-825980	E	20010404

OTHER SOURCE(S): MARPAT 135:303769

GI



I

AB This invention relates to compds. represented by formula [I; R1 = pyrrolidin-1-yl, 2-oxopyrrolidin-1-yl, 2-hydroxy-1-pyrrolidin-1-yl, 2-methoxy-1-pyrrolidin-1-yl, NH(CH2)3COR6 (where R6 = OH, NHCH2CO2H); R2, R3, R4, R7 = H, OH, OMe; provided that (a) if R1 is pyrrolidin-1-yl or NH(CH2)3CO2H, and (b) R2 is OH or OMe and R3 and R7 are H, or if R1 is defined in (a) and (c) R2 and R7 are H and R3 is OH or OMe, then R4 is not H] which are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin- 1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol (PPTN) and are believed to possess

significant pharmacol. activities similar or identical to those possessed by the parent PPTN. The compds. of the invention can be used as stds. for anal. assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compns. for the treatment of disease and methods of treating disease. Examples of diseases or conditions for which the compds. can be effective include osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, etc. (no data). Thus, 1-[2-[4-(2-Bromo-6,7- dimethoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine was coupled with phenylboronic acid in the presence of tetrakis(triphenylphosphine)pal ladium and Na2CO3 in EtOH at room temperature for 10 h to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine which was hydrogenated Pd(OH)2 on carbon in a mixture of 2 N aqueous HCl, H2O, and EtOH at 50° under a H atmospheric of 30 psi to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine. The latter compound was heated in a mixture of AcOH and 48% aqueous HBr at 90° for 2 h to give cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2,3-diol and a mixture of cis-3-methoxy-7-phenyl-8-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and cis-3-methoxy-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol.

IT 180916-16-9
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(animal metabolism; preparation of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:559558 HCAPLUS Full-text

DOCUMENT NUMBER: 135:142234
TITLE: Compositions and methods for treating conditions responsive to estrogen
INVENTOR(S): Thompson, David Duane; Lee, Andrew George; Day, Wesley Warren; Rosati, Robert Louis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1120114	A2	20010801	EP 2001-300221	20010111
EP 1120114	A3	20030820		
EP 1120114	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
ZA 2001000177	A	20020708	ZA 2001-177	20010108
TW 246918	B	20060111	TW 2001-90100370	20010108
CA 2331053	A1	20010712	CA 2001-2331053	20010110
CA 2331053	C	20051025		
CA 2475393	A1	20010712	CA 2001-2475393	20010110
US 2001041718	A1	20011115	US 2001-758778	20010111
US 6632834	B2	20031014		
NZ 509321	A	20021025	NZ 2001-509321	20010111
HU 200100120	A2	20021028	HU 2001-120	20010111
AU 780142	B2	20050303	AU 2001-13676	20010111
AT 345794	T	20061215	AT 2001-300221	20010111
JP 2001213776	A	20010807	JP 2001-4452	20010112
US 2004092506	A1	20040513	US 2003-652186	20030829

PRIORITY APPLN. INFO.:
US 2000-175752P P 20000112
CA 2001-2331053 A3 20010110
US 2001-758778 A3 20010111

OTHER SOURCE(S): MARPAT 135:142234

AB This invention relates to methods, pharmaceutical compns. and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compns. include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. The in vitro antiproliferative effects of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8- tetrahydronaphthalene-2-ol were tested in 2 types of human breast cancer cell lines: first, MCF-7 cells, which contain ER as well as progesterone receptors (PgR), and second, MDA-MB-231 cells, which lack ER and PgR, and enable the determination of an effect that is independent of the ER mechanism. Growth inhibition was ER-specific and not due to cytotoxicity since the compound had no measurable effect on the ER-neg. cell line.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treating conditions responsive to estrogen)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:450913 HCAPLUS Full-text

DOCUMENT NUMBER: 129:184100

TITLE: Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene

AUTHOR(S): Rosati, Robert L.; Jardine, Paul Da Silva; Cameron, Kimberly O.; Thompson, David D.; Ke, Hua Zhu; Toler, Steven M.; Brown, Thomas A.; Pan, Lydia C.; Ebbinghaus, Charles F.; Reinhold, Anthony R.; Elliott, Nancy C.; Newhouse, Bradley N.; Tjoa, Christina M.; Sweetnam, Paul M.; Cole, Mark J.; Arriola, Mark W.; Gauthier, Jeffrey W.; Crawford, D. Todd; Nickerson, David F.; Pirie, Christine M.; Qi, Hong; Simmons, Hollis A.; Tkalcevic, George T.

CORPORATE SOURCE: Central Research Division, Pfizer Inc., Groton, CT, 06340, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(16), 2928-2931
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB CP-336156 (I), a nonsteroidal estrogen agonist/antagonist with excellent oral bioavailability, was prepared and is as potent and efficacious as estrogen at preventing bone loss and lowering total serum cholesterol in rats. In addition, estrogen-like proliferative effects on breast and uterine tissue were not observed The superior oral kinetics, achieved by minimizing intestinal glucuronidation through the application of a structural model, translated into a breakthrough for in vivo potency.

IT 180916-16-9P, 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and preclin. pharmacol. of a potent, nonsteroidal estrogen agonist/antagonist, CP-336156)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que l18
L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON 180916-16-9/RN
L2 SEL PLU=ON L1 1- CHEM : 2 TERMS

```
L3          136 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2
L5       260272 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("INFLAMMATORY BOWEL DISEASE"/
                CV OR "INTESTINE, DISEASE (L) INFLAMMATORY"/CV) OR BOWEL OR
                INTESTIN?
L6           16 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L5
L7            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L)?INFLAMM?
L8           17 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 OR L7
L12         262 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("MACLEAN DAVID"/AU OR
                "MACLEAN DAVID A"/AU OR "MACLEAN DAVID B"/AU OR "MACLEAN DAVID
                BAILEY"/AU OR "MACLEAN DAVID BARKER"/AU OR "MACLEAN DAVID
                BURTON"/AU) OR MACLEAN D/AU OR MACLEAN D B/AU
L13         421 SEA FILE=HCAPLUS ABB=ON  PLU=ON  THOMPSON D/AU OR THOMPSON D
                D/AU OR "THOMPSON DAVID"/AU OR ("THOMPSON DAVID D"/AU OR
                "THOMPSON DAVID DUANE"/AU)
L14          20 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 AND L13
L15          25 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L12 OR L13) AND L3
L16          11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L12 OR L13) AND L5
L17          49 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 OR L15 OR L16
L18          46 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 NOT L8


=>
=>

=> d ibib abs hitstr l18 1-46

L18  ANSWER 1 OF 46  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1156816  HCAPLUS  Full-text
DOCUMENT NUMBER:          145:465947
TITLE:                    Pharmaceutical compositions and methods comprising a
                          combination of a selective estrogen receptor modulator
                          and an aromatase inhibitor
INVENTOR(S):              Curto, Madelyn; Sisson, Melanie; Lee, Andrew George;
                          Thompson, David Duane
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   PCT Int. Appl., 29pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     --------------       ----   --------    -------------------     --------
     WO 2006114702         A2    20061102    WO 2006-IB1040          20060413
     WO 2006114702         A3    20070104
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
```

JP 2006306872 A 20061109 JP 2006-118713 20060424
PRIORITY APPLN. INFO.: US 2005-674807P P 20050425

AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)- phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug thereof and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8- tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug and an aromatase inhibitor selected from aminoglutethimide; formestane; atamestane; anastrazole; fadrozole; finrozole; letrozole; vorozole; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1 ,2,4-triazole or exemestane, or a pharmaceutically acceptable salt thereof.

IT 180916-16-9
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 2 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1019408 HCAPLUS Full-text
DOCUMENT NUMBER: 146:75472
TITLE: Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes
AUTHOR(S): Fung, Michelle; Thompson, David; Shapiro, R. Jean; Warnock, Garth L.; Andersen, Dana K.; Elahi, Dariush; Meneilly, Graydon S.
CORPORATE SOURCE: Department of Medicine, University of British Columbia, Vancouver, BC, Can.
SOURCE: Diabetes Research and Clinical Practice (2006), 74(2), 189-193

CODEN: DRCPE9; ISSN: 0168-8227
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 mo after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118 ± 29 pM; type 2 diabetes: 68 ± 20 pM; transplant: 99 ± 18 pM, p = ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108 ± 344 pM; type 2 diabetes: 929 ± 331 pM; transplant: 329 ± 112 pM, p < 0.0001 control vs. transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respond to GLP-1.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:878823 HCAPLUS Full-text
DOCUMENT NUMBER: 146:26080
TITLE: Expression of TECK/CCL25 and MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine mucosal tissues
AUTHOR(S): Meurens, Francois; Berri, Mustapha; Whale, Julia; Dybvig, Tova; Strom, Stacy; Thompson, David; Brownlie, Robert; Townsend, Hugh G. G.; Salmon, Henri; Gerdts, Volker
CORPORATE SOURCE: Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, S7N 5E3, Can.
SOURCE: Veterinary Immunology and Immunopathology (2006), 113(3-4), 313-327
CODEN: VIIMDS; ISSN: 0165-2427
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB CCL25 and CCL28 (also named TECK and MEC) are CC chemokines primarily expressed by thymic dendritic cells and mucosal epithelial cells. The cognate receptors of CCL25 and CCL28, named CCR9 and CCR10, are mainly expressed on T lymphocytes for CCR9 and IgA+ and IgM+ plasmablasts for CCR9 and CCR10, resp. In human and mouse, chemokines CCL25 and CCL28 play an important role in attracting immune cells to the gastrointestinal tract and in controlling segmental specialization of the intestinal immune system. To investigate if CCL25 and CCL28 play a similar role in the pig and to better understand lymphocyte trafficking in this species, the authors cloned porcine CCL25 and CCR10 and measured expression of CCL25, CCL28, CCR9, and CCR10 transcripts by real-time and conventional PCR in various tissues from newborn and young piglets, and adult sows. The results of the expression analyses show that (1) expression of CCL25 mRNA is mainly restricted to the small intestine, (2) CCL28 mRNA expression is detectable in all tested epithelial mucosal surfaces with the highest levels of expression in the mammary gland, trachea and large

intestine, (3) high levels of expression of CCR9 mRNA in CD3+ T lymphocytes, gut-associated lymphoid tissues (GALT), and the small intestine, (4) high levels of expression of CCR10 mRNA in GALT, the large intestine, the small intestine, and the mammary gland, and (5) up-regulation of CCL28 mRNA expression during lactation in the mammary gland. This pattern of expression, which is discussed in the context of compartmentalization of the porcine common mucosal immune system into upper aero-digestive tract, small intestine, and large intestine, suggests a key role for CCL28 in the recruitment of IgA secreting cells into the mammary gland enabling the passive transfer of IgA antibodies from mother to infant.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004350 HCAPLUS Full-text
DOCUMENT NUMBER: 143:306176
TITLE: Preparation of heterocyclic compounds as EP2 selective receptor agonists for treating pulmonary hypertension and other conditions
INVENTOR(S): Constan, Alexander A.; Keshary, Prakash; MacLean, David B.; Paralkar, Vishwas M.; Roman, Doina; Thompson, David D.; Wright, Timothy M.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 82 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203086	A1	20050915	US 2004-793530	20040304
PRIORITY APPLN. INFO.:			US 2004-793530	20040304

OTHER SOURCE(S): MARPAT 143:306176
GI



I

AB The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using the compds. I [A = SO2, CO; G = Ar, Ar(alkylene), ArCONH(alkylene), etc.; B = N, CH; Q = alkylene, X(alkylene), X(alkylene), etc.; Z = carboxy, alkoxycarbonyl, tetrazolyl, etc.; K = a bond,

alkylene, thioalkylene, etc.; M = Ar3, Ar4SAr5, Ar4OAr5, etc.; Ar, Ar3-Ar5 = partially saturated or fully unsatd. 5-8 membered ring having 1-4 heteroatoms selected from O, S, N, or a bicyclic ring, tricycling ring, etc.; X = X = 5-6 membered aromatic ring optionally having 1-2 heteroatoms selected from O, N and S], an EP2 selective receptor agonists. Syntheses of representative compds. I and their intermediates are described in several examples. E.g., a 3-step synthesis of 7-[(4-butylbenzyl)-(pyridine-3-sulfonyl)amino]heptanoic acid, starting from Me 7-aminoheptanoate (preparation given) and 4-butylbenzaldehyde, was given. The compds. I were tested for binding to prostaglandin E2 receptors (data given for exemplified compds. I).

L18 ANSWER 5 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:259665 HCAPLUS Full-text
DOCUMENT NUMBER: 142:310360
TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
INVENTOR(S): Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065134	A1	20050324	US 2004-944368	20040916
WO 2005027925	A1	20050331	WO 2004-IB2904	20040906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-504510P P 20030919
OTHER SOURCE(S): CASREACT 142:310360
AB The present invention relates to methods of treating anorexia or low bone mass in females exhibiting aggressive athletic behavior, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative Particularly, the present invention relates to methods of treating anorexia or low bone mass in females exhibiting aggressive athletic behavior, the methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)- 1α,25-dihydroxy-vitamin D3.

L18 ANSWER 6 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:259663 HCAPLUS Full-text
DOCUMENT NUMBER: 142:310359
TITLE: Preparation of 2-alkylidene-19-nor-vitamin D

derivatives for the treatment or prevention of a second hip fracture
INVENTOR(S): Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065132	A1	20050324	US 2004-944065	20040916
WO 2005027919	A1	20050331	WO 2004-IB2914	20040906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-504004P P 20030919
OTHER SOURCE(S): CASREACT 142:310359

AB The present invention relates to methods of treating or preventing a second hip fracture, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative Particularly, the present invention relates to methods of treating or preventing a second hip fracture, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)- 1α,25-dihydroxyvitamin D 3.

L18 ANSWER 7 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:259662 HCAPLUS Full-text
DOCUMENT NUMBER: 142:310358
TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for enhancement of peak bone mass in adolescence
INVENTOR(S): Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065131	A1	20050324	US 2004-944063	20040916
WO 2005027927	A1	20050331	WO 2004-IB2906	20040906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-504511P P 20030919
OTHER SOURCE(S): CASREACT 142:310358

AB The present invention relates to methods of enhancing peak bone mass in adolescence, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative Particularly, the present invention relates to methods of enhancing peak bone mass in adolescence, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3.

L18 ANSWER 8 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1050178 HCAPLUS Full-text
DOCUMENT NUMBER: 142:253438
TITLE: Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies
AUTHOR(S): Maeda, Tomoko; Ke, Hua Zhu; Simmons, Hollis; Thompson, David
CORPORATE SOURCE: Tokyo Laboratories, Clinical Research, Pfizer Japan Inc. Pfizer Global Research and Development, Japan
SOURCE: Clinical Calcium (2004), 14(10), 1555-1563
CODEN: CLCCEJ; ISSN: 0917-5857
PUBLISHER: Iyaku Janarusha
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review. Estrogen replacement therapy, in spite of efficacy in the prevention of osteoporotic fractures, has significant side effects and risks that limit its widespread usage in postmenopausal women. Thus significant medical need exists to find modalities that prevent osteoporosis, but without the side effects of estrogen. Selective estrogen receptor modulators (SERMs) have the potential to provide the skeletal benefits of estrogen without the increased risk of uterine and breast cancer. Tamoxifen, a first generation SERM is approved for the prevention and treatment of breast cancer, and raloxifene, a second generation SERM has been approved for the prevention and treatment of osteoporosis. Lasofoxifene, a new potent, nonsteroidal SERM, binds with high affinity to human estrogen receptors and acts as a tissue selective estrogen antagonist or agonist. In preclin. models of postmenopausal osteoporosis, lasofoxifene inhibited bone turnover and prevented bone loss throughout the skeleton. In studies designed to investigate the combination of lasofoxifene with estrogen, lasofoxifene blocked the hypertrophic effects of estrogen in the uterus, but did not block the bone protective effects. In immature and aged female rats, lasofoxifene did not affect the uterine weight and uterine histol. In preclin. studies designed to evaluate the effects of lasofoxifene on the uterus, a slight increase in wet uterine weight was observed in immature and aged female rats, but this difference was not observed in dry uterine weight suggesting that the increased uterine weight was due to increased water content in the tissue. In preclin. studies designed to evaluate the effects of lasofoxifene in breast cancer, lasofoxifene inhibited breast tumor formation in mice injected with

human MCF-7 breast cancer cells and in rats bearing mammary carcinomas. Thus, in preclin. models, lasofoxifene, a next generation SERM, prevents estrogen deficiency-induced bone loss, inhibits breast tumor formation, and reduces serum cholesterol, without causing uterine hypertrophy. These data suggest that lasofoxifene is a new potential therapy for the prevention of osteoporosis in postmenopausal women.

IT 180916-16-9, Lasofoxifene
RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene, a next generation estrogen receptor modulator for treatment of postmenopausal osteoporosis)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 9 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:754428 HCAPLUS Full-text
DOCUMENT NUMBER: 141:254616
TITLE: Use of EP2 selective receptor agonists in medical treatment of pulmonary hypertension and other conditions
INVENTOR(S): Constan, Alexander Angelo; Keshary, Prakash Raj; MacLean, David Burton; Paralkar, Vishwas Madhav; Roman, Doina Cosma; Thompson, David Duane; Wright, Timothy Michael
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078169	A1	20040916	WO 2004-IB553	20040223
WO 2004078169	A8	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004216898	A1	20040916	AU 2004-216898	20040223
CA 2518193	A1	20040916	CA 2004-2518193	20040223
EP 1601351	A1	20051207	EP 2004-713611	20040223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004008061	A	20060214	BR 2004-8061	20040223
JP 2006519250	T	20060824	JP 2006-506276	20040223
CN 1859903	A	20061108	CN 2004-80008576	20040223
PRIORITY APPLN. INFO.:			US 2003-451889P P	20030304
			WO 2004-IB553 A	20040223

OTHER SOURCE(S): MARPAT 141:254616

AB The invention discloses methods for treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist. Preparation of compds., e.g. 7-[(4-butylbenzyl)-(pyridine-3- sulfonyl)amino]heptanoic acid, is described.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:260137 HCAPLUS Full-text

DOCUMENT NUMBER: 140:350501

TITLE: Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

AUTHOR(S): Ke, Hua Zhu; Foley, George L.; Simmons, Hollis A.; Shen, Victor; Thompson, David D.

CORPORATE SOURCE: Pfizer Global Research and Development, Groton Laboratories, Groton, CT, 06340, USA

SOURCE: Endocrinology (2004), 145(4), 1996-2005
CODEN: ENDOAO; ISSN: 0013-7227

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to determine the long-term effects of lasofoxifene, a new selective estrogen receptor modulator, on bone mass, bone strength, and reproductive tissues in ovariectomized (OVX) rats. Sprague Dawley female rats at 3.5 mo of age were OVX and treated orally with lasofoxifene (60, 150, or 300 μg/kg·d) for 52 wk. The urinary deoxypyridinoline/creatinine ratio was significantly lower in all lasofoxifene-treated OVX rats compared with OVX controls at wk 26. Peripheral quant. computerized tomog. anal. of proximal tibial metaphysis showed that the significant loss in trabecular content and d. induced by OVX was significantly prevented by lasofoxifene treatment. Proximal tibial and lumbar vertebral trabecular bone histomorphometric anal. showed that all doses of lasofoxifene

significantly reduced OVX-induced bone loss by decreasing bone resorption and bone turnover. The ultimate strength, energy, and toughness of the fourth lumbar vertebral body in OVX rats treated with all doses of lasofoxifene were significantly higher compared with those in OVX controls, and did not differ significantly from those in sham controls. Uterine weight in OVX rats treated with lasofoxifene was slightly, but significantly, higher when compared with that in OVX controls, but was still much less than that in sham controls. No abnormal finding associated with lasofoxifene was observed with uterine histol. examination In summary, long-term treatment with lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in OVX rats. These data suggest that lasofoxifene is an effective antiosteoporosis agent, and its efficacy and safety can be maintained over an extended period of time.

IT 180916-16-9, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affectuterus in ovariectomized rats)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:336422 HCAPLUS Full-text

DOCUMENT NUMBER: 139:316344

TITLE: Lasofoxifene (CP-336156), a novel selective estrogen receptor modulator, in preclinical studies

AUTHOR(S): Ke, H. Z.; Brown, T. A.; Thompson, D. D.

CORPORATE SOURCE: Osteoporosis Research, Pfizer Global Research and Development, Groton Laboratories, Groton, CT, USA

SOURCE: Journal of the American Aging Association (2002), 25(2), 87-99
CODEN: JAAABY

PUBLISHER: Journal of the American Aging Association

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Estrogen replacement therapy is reported to reduce the incidence of vertebral fractures in postmenopausal women, however, its compliance is limited because of side effects and safety concerns. Estrogen's side effects on breast and uterine tissues leading to the potential increased risk of uterine and breast cancer limit widespread estrogen usage. Thus, there is a significant medical need for a therapy that protects against postmenopausal bone loss but is free of estrogen's neg. effects on reproductive tissues. Selective estrogen receptor modulators (SERMs) have been investigated as an alternative to hormone replacement therapy. One such compound, raloxifene, has been approved for the prevention and treatment of osteoporosis. Lasofoxifene (LAS), a new, nonsteroidal, and potent SERM, is an estrogen antagonist or agonist depending on the target tissue. LAS selectively binds with high affinity to human estrogen receptors. In ovariectomized (OVX) rat studies, LAS prevented the decrease in femoral bone mineral d., tibial and lumbar vertebral trabecular bone mass at an ED100 of about 60 μg/kg/day. LAS inhibited the activation of trabecular and endocortical bone resorption and bone turnover in tibial metaphyses and diaphyses, and lumbar vertebral body in OVX rats. In addition, LAS decreased total serum cholesterol, inhibited body weight gain and increased soleus muscle weight in OVX rats. Similarly, LAS prevented bone loss induced by orchidectomy or aging in male rats by decreasing bone resorption and bone turnover while it had no effect in the prostate. Further, LAS decreased total serum cholesterol in intact aged male rats or in orchidectomized male rats. Synergestic skeletal effects were found with LAS in combination with bone anabolic agents such as prostaglandin E2 (PGE2), parathyroid hormone (PTH) or a growth hormone secretagogue (GHS) in OVX rats. In combination with estrogen, LAS inhibited the uterine stimulating effects of estrogen but did not block the bone protective effects of estrogen. In immature and aged female rats, LAS did not affect the uterine weight and uterine histol. In OVX adult female rats, LAS slightly but significantly increased uterine weight These results demonstrated that LAS produced effects on the skeleton indistinguishable from estrogen in female and male rats. However, unlike estrogen, LAS had little effect on uterine weight and cellular proliferation of uterus in female rats. In preclin. anti-tumor studies, LAS inhibited human breast cancer growth in mice bearing MCF7 tumors, prevented NMU-induced mammary carcinomas and possessed chemotherapeutic effects in NMU-induced carcinomas in rats. Therefore, we conclude that LAS possesses the antiestrogenic effects in breast tissue and estrogenic effects in bone and serum cholesterol, but lacks estrogen's side effects on uterine tissue. These data support the therapeutic potential of LAS for the prevention and treatment of postmenopausal bone loss and mammary carcinomas in humans.

IT 180916-16-9, Lasofoxifene
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene (CP-336156), a novel selective estrogen receptor modulator, in preclin. studies)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:117617 HCAPLUS Full-text
DOCUMENT NUMBER: 138:147771
TITLE: Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
INVENTOR(S): Ke, Hua Zhu; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011282	A1	20030213	WO 2002-IB2763	20020704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448235	A1	20030213	CA 2002-2448235	20020704
NZ 529511	A	20031219	NZ 2002-529511	20020704
EP 1411922	A1	20040428	EP 2002-743537	20020704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 200401268	A2	20041129	HU 2004-1268	20020704
JP 2005504032	T	20050210	JP 2003-516512	20020704
CN 1599606	A	20050323	CN 2002-813867	20020704
US 2003065017	A1	20030403	US 2002-206587	20020726
US 7030157	B2	20060418		

ZA 2003008809 A 20041123 ZA 2003-8809 20031112
PRIORITY APPLN. INFO.: US 2001-309065P P 20010731
WO 2002-IB2763 W 20020704

AB The present invention relates to pharmaceutical compns., kits and methods comprising combinations of lasofoxifene ((-)-cis-6-phenyl-5-[4- (2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol) or nontoxic pharmacol. acceptable acid addition salts thereof and estrogens. The present invention also relates to pharmaceutical compns., kits and methods comprising combinations of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1- yl-ethoxy)-phenyl]-5,6, 7 ,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacol. acceptable acid addition salts thereof, estrogens and progestins. In the examples provided, lasofoxifene tartrate alone or in combination with 17β-ethynylestradiol completely reversed ovariectomy-induced bone loss in rats and antagonized the uterine hypertrophy effects induced by the estrogen.

IT 180916-16-9, Lasofoxifene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene, estrogen and progestin for treatment of osteoporosis and sexual dysfunctions)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:82249 HCAPLUS Full-text
DOCUMENT NUMBER: 138:281406
TITLE: Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans
AUTHOR(S): Burdyga, Galina; Lal, Simon; Spiller, David; Jiang, Wen; Thompson, David; Attwood, Stephen; Saeed, Shakeel; Grundy, David; Varro, Andrea; Dimaline, Rod; Dockray, Graham J.
CORPORATE SOURCE: Department of Physiology, University of Liverpool, Liverpool, UK
SOURCE: Gastroenterology (2003), 124(1), 129-139
CODEN: GASTAB; ISSN: 0016-5085
PUBLISHER: W. B. Saunders Co.

DOCUMENT TYPE: Journal
LANGUAGE: English
AB Orexin-A and -B are brain-gut peptides that stimulate food intake via orexin-R1 and -R2 receptors. Cholecystokinin (CCK) inhibits food intake via CCKA receptors expressed on vagal afferent neurons. The purpose of the study was to determine whether vagal afferent neurons express OX-R1 and OX-R2 and whether orexin-A inhibits responses to CCK. OX-R1 and -R2 expression by rat and human nodose ganglia was examined by reverse-transcriptase polymerase chain reaction (RT-PCR). Receptor localization was determined by immunohistochem. Responses of rat jejunal afferent fibers were examined by electrophysiol. Both rat and human nodose ganglia expressed OX-R1 as detected by RT-PCR, and humans also expressed OX-R2. The identity of the products was confirmed by sequencing. Immunohistochem. indicated expression of OX-R1 in both species in neurons that also expressed CCKA and leptin receptors. In human ganglia there was also expression in glial cells that was absent in rats. Orexin-A had no effect on the resting discharge of afferent nerve fibers but inhibited responses to CCK. OX-R1 and CCKA receptors are expressed by human and rat vagal afferent neurons. Orexin inhibits responses to CCK suggesting a role in modulation of gut to brain signaling.
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:52767 HCAPLUS Full-text
DOCUMENT NUMBER: 139:358454
TITLE: Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs): discovery of capromorelin
AUTHOR(S): Carpino, Philip A.; Lefker, Bruce A.; Toler, Steven M.; Pan, Lydia C.; Hadcock, John R.; Cook, Ewell R.; DiBrino, Joseph N.; Campeta, Anthony M.; DeNinno, Shari L.; Chidsey-Frink, Kristin L.; Hada, William A.; Inthavongsay, John; Mangano, F. Michael; Mullins, Michelle A.; Nickerson, David F.; Ng, Oicheng; Pirie, Christine M.; Ragan, John A.; Rose, Colin R.; Tess, David A.; Wright, Ann S.; Yu, Li; Zawistoski, Michael P.; DaSilva-Jardine, Paul A.; Wilson, Theresa C.; Thompson, David D.
CORPORATE SOURCE: Groton Labs, Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(4), 581-590
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:358454
AB Novel pyrazolinone-piperidine dipeptide derivs. were synthesized and evaluated as growth hormone secretagogues (GHSs). Two analogs, capromorelin (5, CP-424391-18, hGHS-R1a Ki=7 nM, rat pituicyte EC50=3 nM) and the des-Me analog 5c (hGHS-R1a Ki=17 nM, rat pituicyte EC50=3 nM), increased plasma GH levels in an anesthetized rat model, with ED50 values less than 0.05 mg/kg iv. Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%]. This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:847483 HCAPLUS Full-text
DOCUMENT NUMBER: 137:333165
TITLE: Methods and kits using an estrogen agonist/antagonist for treating depression or preventing deterioration of cognitive function
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Petrie, Charles David; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1254662	A2	20021106	EP 2002-252391		20020402
EP 1254662	A3	20030521			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AU 2002027566	A5	20021031	AU 2002-27566		20020321
CN 1382440	A	20021204	CN 2002-105674		20020417
CA 2383175	A1	20021025	CA 2002-2383175		20020423
US 2003092719	A1	20030515	US 2002-132907		20020424
HU 200201356	A2	20030828	HU 2002-1356		20020424
NZ 518569	A	20030926	NZ 2002-518569		20020424
ZA 2002003253	A	20031024	ZA 2002-3253		20020424
JP 2002332232	A	20021122	JP 2002-123544		20020425
US 2005080099	A1	20050414	US 2004-956896		20040930
PRIORITY APPLN. INFO.:			US 2001-286433P	P	20010425
			US 2002-132907	A3	20020424

OTHER SOURCE(S): MARPAT 137:333165
GI



I

AB The invention provides methods and kits for treating depression, perimenopausal depression, schizophrenia, anxiety, panic attacks, binge eating, social phobia, or preventing deterioration of cognitive function by administering to a patient in need thereof a therapeutically effect amount of an estrogen agonist/antagonist I [A = CH2, NR; R = H, C1-6 alkyl; B, D, E = CH, N; Y = (substituted) Ph, (substituted) naphthyl, (substituted) C3-8 cycloalkyl, etc.; Z1 = OCHR2CHR3, SCHR2CHR3, etc.; R2, R3 = H, C1-4 alkyl; G =

NR7R8, C5-12 bicyclic amine, etc.; R7, R8 = Ph, C3-10 (un)saturated carbocyclic ring, etc.; e = 0-2].

IT 180916-16-9 180916-16-9D, isomers and derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonist/antagonist for treating depression and other conditions)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 16 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:314396 HCAPLUS Full-text
DOCUMENT NUMBER: 136:319399
TITLE: Use of an estrogen agonist/antagonist for improving vascular health

INVENTOR(S): Day, Wesley W.; Lee, Andrew G.; Thompson, D.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199071	A2	20020424	EP 2001-308806	20011016
EP 1199071	A3	20031029		
EP 1199071	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 778095	B2	20041118	AU 2001-79392	20011012
CA 2358840	A1	20020417	CA 2001-2358840	20011015
US 2002156090	A1	20021024	US 2001-977458	20011015
US 6620806	B2	20030916		
ZA 2001008444	A	20030415	ZA 2001-8444	20011015
JP 2002145773	A	20020522	JP 2001-317833	20011016
HU 200104338	A2	20020729	HU 2001-4338	20011016
NZ 514847	A	20030630	NZ 2001-514847	20011016
AT 326962	T	20060615	AT 2001-308806	20011016
PT 1199071	T	20060929	PT 2001-308806	20011016

PRIORITY APPLN. INFO.: US 2000-241532P P 20001017
OTHER SOURCE(S): MARPAT 136:319399

AB The invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.

IT 180916-16-9 180916-16-9D, salts, N-oxides, and esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of estrogen agonist/antagonist for improving vascular health)
RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 17 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:640004 HCAPLUS Full-text
TITLE: Short- and long-acting growth hormone secretagogues (GHSs): Discovery and SAR of CP-424391-18 (capromorelin tartrate) and CP-464709-18
AUTHOR(S): Carpino, Philip A.; Lefker, Bruce A.; Toler, Steven M.; Pan, Lydia C.; Hadcock, John R.; Murray, Marianne C.; Cook, Ewell R.; Dibrino, Joseph N.; De Ninno, Shari L.; Chidsey-Frink, Kristin L.; Hada, William A.; Inthavongsay, John; Lewis, Sharon K.; Mangano, F. Michael; Mullins, Michelle A.; Nickerson, David F.; Ng, Oicheng; Pirie, Christine M.; Ragan, John A.; Rose, Colin R.; Tess, David A.; Wright, Ann S.; Yu, Li; Zawistoski, Michael P.; MacLean, David B. ; Pettersen, John C.; Da Silva-Jardine, Paul A.; Wilson, Theresa C.; Thompson, David D.
CORPORATE SOURCE: Department of Cardiovascular & Metabolic Diseases, Pfizer Global Research & Development - Groton Labs,

Groton, CT, 06340, USA
SOURCE: Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001 (2001), MEDI-185. American Chemical Society: Washington, D. C.
CODEN: 69BUZP
DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English
AB Growth hormone secretagogues (GHSs) are a new class of drugs that stimulate pituitary growth hormone (GH) secretion and increase plasma insulin growth factor-1 (IGF-1) levels. We have discovered a new series of pyrazolinone-piperidine dipeptide GHSs with good in vitro and in vivo activities. CP-424391-18 (capromorelin tartrate) is a short-acting GHS with good bioavailability in the beagle dog [dog t1/2=1.3 h; F(dog)=44%)]. CP-464709-18 is a longer-duration GHS that was identified from capromorelin by blocking potential sites of metabolism [dog t1/2=4.1 h; F(dog)=77%]. Both capromorelin and CP-464709-18 are in human clin. trials. The syntheses, pharmacol. characterizations and structure-activity relationships (SAR) of these GHSs will be presented.

L18 ANSWER 18 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:615491 HCAPLUS Full-text
DOCUMENT NUMBER: 135:180782
TITLE: Use of estrogen agonists/antagonists for the treatment of sexual dysfunction
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 45 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1125582	A2	20010822	EP 2001-300061		20010105
EP 1125582	A3	20020417			
EP 1125582	B1	20060802			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR					
AT 334674	T	20060815	AT 2001-300061		20010105
ZA 2001000176	A	20020708	ZA 2001-176		20010108
CA 2331009	A1	20010712	CA 2001-2331009		20010110
CA 2331009	C	20051025			
JP 2001233791	A	20010828	JP 2001-2462		20010110
US 2001044434	A1	20011122	US 2001-757423		20010110
US 6512002	B2	20030128			
AU 784439	B2	20060406	AU 2001-11129		20010110
NZ 509320	A	20020628	NZ 2001-509320		20010111
HU 200100121	A2	20021028	HU 2001-121		20010111
US 2003114440	A1	20030619	US 2002-301930		20021121
PRIORITY APPLN. INFO.:			US 2000-175704P	P	20000112
			US 2001-757423	A3	20010110

OTHER SOURCE(S): MARPAT 135:180782
GI



I

AB Pyridinylpyrazolopyrimidinone cGMP PDEv inhibitors, e.g., I were prepared Data for biol. activity of 3-[1-[4-(2-dimethylaminoethoxy)phenyl]-2-phenyl- 1-butenyl]phenol were given.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of estrogen agonists/antagonists for the treatment of sexual dysfunction)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 19 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:555210 HCAPLUS Full-text

DOCUMENT NUMBER: 135:142233

TITLE: Pharmaceutical compositions containing estrogen agonist/antagonist and statins for treatment of osteoporosis and/or for lowering blood cholesterol

INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2001206845	A	20010731	JP 2001-15626		20010124
EP 1123717	A2	20010816	EP 2001-300527		20010122
EP 1123717	A3	20031015			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 2003162807	A1	20030828	US 2001-767625		20010123
US 6756401	B2	20040629			
CA 2332214	A1	20010726	CA 2001-2332214		20010124
ZA 2001000675	A	20020724	ZA 2001-675		20010124
AU 2001016675	A5	20010802	AU 2001-16675		20010125
AU 780568	B2	20050407			
HU 200100388	A2	20030828	HU 2001-388		20010125
NZ 523651	A	20040625	NZ 2001-523651		20010125
US 2004259886	A1	20041223	US 2004-840577		20040506
AU 2005200655	A1	20050310	AU 2005-200655		20050214
PRIORITY APPLN. INFO.:			US 2000-188923P	P	20000126
			US 2000-205327P	P	20000421
			US 2001-767625	A3	20010123

OTHER SOURCE(S): MARPAT 135:142233

AB The invention provides a composition containing an estrogen agonist/antagonist, and a statin deriv for treatment of osteoporosis and/or for lowering blood cholesterol. The antiosteoporotic effect of (-)-cis-6-phenyl-5-[4-(2- pyrrolidine-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol (PPTN) in ovary-excised rats were examined

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing estrogen agonist/antagonist and statins for treatment of osteoporosis and/or for lowering blood cholesterol)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 20 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:541600 HCAPLUS Full-text
DOCUMENT NUMBER: 135:117261
TITLE: Method using estrogen agonists/antagonists for reducing morbidity and the risk of mortality from cardiovascular disease, breast cancer, and osteoporosis
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1118323	A2	20010725	EP 2001-300159		20010109
EP 1118323	A3	20030521			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
CA 2331059	A1	20010712	CA 2001-2331059		20010110
US 2001056099	A1	20011227	US 2001-757817		20010110
ZA 2001000276	A	20020710	ZA 2001-276		20010110
HU 200100119	A2	20021028	HU 2001-119		20010111
JP 2001226265	A	20010821	JP 2001-5300		20010112
PRIORITY APPLN. INFO.:			US 2000-175663P	P	20000112

OTHER SOURCE(S): MARPAT 135:117261

AB The invention discloses methods, pharmaceutical compns., and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined reduction of breast cancer, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and osteoporosis)
RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 180916-16-9D, isomers, N-oxides, esters, and prodrug derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and osteoporosis)
RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 21 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:454559 HCAPLUS Full-text
DOCUMENT NUMBER: 138:100848
TITLE: Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue. [Erratum to document cited in CA135:87127]
AUTHOR(S): Pan, Lydia C.; Carpino, Philip A.; Lefker, Bruce A.; Ragan, John A.; Toler, Steven M.; Pettersen, John C.; Nettleton, David O.; Ng, Oicheng; Pirie, Christine M.; Chidsey-Frink, Kristin; Lu, Bihong; Nickerson, David F.; Tess, David A.; Mullins, Michelle A.; MacLean, David B.; Da Silva-Jardine, Paul A.; Thompson, David D.
CORPORATE SOURCE: Global Research & Development, Pfizer Inc., Groton, CT, USA
SOURCE: Endocrine (2001), 14(3), 437
CODEN: EOCRE5; ISSN: 1355-008X
PUBLISHER: Humana Press Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In the article, CP-424,391 was incorrectly described as a pyrazolidinone-piperidine dipeptide; it should be a pyrazolinone- piperidine dipeptide GHS.

L18 ANSWER 22 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:274749 HCAPLUS Full-text
DOCUMENT NUMBER: 135:205314
TITLE: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats
AUTHOR(S): Ke, Hua Zhu; Qi, Hong; Chidsey-Frink, Kristin L.; Crawford, D. Todd; Thompson, David D.
CORPORATE SOURCE: Osteoporosis Research, Department of Cardiovascular and Metabolic Diseases, Global Research and Development, Pfizer, Incorporated, Groton, CT, USA
SOURCE: Journal of Bone and Mineral Research (2001), 16(4), 765-773
CODEN: JBMREJ; ISSN: 0884-0431
PUBLISHER: American Society for Bone and Mineral Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of this study was to evaluate if long-term (6 mo) treatment with lasofoxifene (LAS), a new selective estrogen receptor modulator (SERM), can protect against age-related changes in bone mass and bone strength in intact aged male rats. Sprague-Dawley male rats at 15 mo of age were treated (daily oral gavage) with either vehicle (n = 12) or LAS at 0.01 mg/kg per day (n = 12) or 0.1 mg/kg per day (n = 11) for 6 mo. A group of 15 rats was necropsied at 15 mo of age and served as basal controls. No significant change was found in body weight between basal and vehicle controls. However, an age-related increase in fat body mass (+42%) and decrease in lean body mass (-8.5%) was observed in controls. Compared with vehicle controls, LAS at both doses significantly decreased body weight and fat body mass but did not affect lean body mass. No significant difference was found in prostate wet weight among all groups. Total serum cholesterol was significantly decreased in all LAS-treated rats compared with both the basal and the vehicle controls. Both doses of LAS treatment completely prevented the age-related increase in serum osteocalcin. Peripheral quant. computerized tomog. (pQCT) anal. at the distal

femoral metaphysis indicated that the age-related decrease in total d., trabecular d., and cortical thickness was completely prevented by treatment with LAS at 0.01 mg/kg per day or 0.1 mg/kg per day. Histomorphometric anal. of proximal tibial cancellous bone showed an age-related decrease in trabecular bone volume (TBV; -46%), trabecular number (Tb.N), wall thickness (W.Th), mineral apposition rate, and bone formation rate-tissue area referent. Moreover, an age-related increase in trabecular separation (Tb.Sp) and eroded surface was observed LAS at 0.01 mg/kg per day or 0.1 mg/kg per day completely prevented these age-related changes in bone mass, bone structure, and bone turnover. Similarly, the age-related decrease in TBV and trabecular thickness (Tb.Th) and the age-related increase in osteoclast number (Oc.N) and osteoclast surface (Oc.S) in the third lumbar vertebral cancellous bone were completely prevented by treatment with LAS at both doses. Further, LAS at both doses completely prevented the age-related decrease in ultimate strength (-47%) and stiffness (-37%) of the fifth lumbar vertebral body. These results show that treatment with LAS for 6 mo in male rats completely prevents the age-related decreases in bone mass and bone strength by inhibiting the increased bone resorption and bone turnover associated with aging. Further, LAS reduced total serum cholesterol and did not affect the prostate weight in these rats. Our data support the potential use of a SERM for protecting against the age-related changes in bone and serum cholesterol in elderly men.

IT 180916-16-9, Lasofoxifene
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lasofoxifene (CP-336,156) protects against age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:254834 HCAPLUS Full-text
DOCUMENT NUMBER: 134:261225
TITLE: Dosage plan of lasofoxifene and related

estrogen agonists and antagonists
INVENTOR(S): Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001097862	A	20010410	JP 2000-297908	20000929
US 6436977	B1	20020820	US 2000-656273	20000906
AU 781828	B2	20050616	AU 2000-56618	20000911
EP 1092431	A2	20010418	EP 2000-308152	20000919
EP 1092431	A3	20020213		
EP 1092431	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 339201	T	20061015	AT 2000-308152	20000919
TW 224001	B	20041121	TW 2000-89119761	20000925
ZA 2000005141	A	20020326	ZA 2000-5141	20000926
CA 2321369	A1	20010329	CA 2000-2321369	20000927
HU 200003836	A2	20011028	HU 2000-3836	20000928
NZ 507200	A	20041224	NZ 2000-507200	20000928
NZ 516413	A	20041224	NZ 2000-516413	20000928

PRIORITY APPLN. INFO.: US 1999-156652P P 19990929

AB Lasofoxifene and related estrogen agonists and antagonists are given orally at 0.8-20 mg for 1-4 wks. for maintaining sustained blood levels for therapeutical purpose.

IT 180916-16-9, Lasofoxifene
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(dosage plan of lasofoxifene and related estrogen agonists and antagonists)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 24 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:257767 HCAPLUS Full-text
DOCUMENT NUMBER: 133:26826
TITLE: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat
AUTHOR(S): Ke, Hua Zhu; Qi, Hong; Crawford, D. Todd; Chidsey-Frink, Kristin L.; Simmons, Hollis A.; Thompson, David D.
CORPORATE SOURCE: Department of Cardiovascular and Metabolic Diseases, Central Research Division, Pfizer, Inc., Groton, CT, 06340, USA
SOURCE: Endocrinology (2000), 141(4), 1338-1344
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB It has been well documented that selective estrogen receptor modulators (SERMs) can prevent bone loss in ovariectomized rats and postmenopausal women. The purposes of this study were to determine the effects of a potent and orally active SERM, lasofoxifene (CP-336,156), on bone mass, bone strength, total serum cholesterol, prostate weight, and histol. in adult male orchidectomized (ORX) rats. Sprague Dawley male rats at 10 mo of age were divided into 6 groups, with 10 rats/group. The first group was necropsied on day 0 and served as basal controls. The remaining rats were either sham operated (n = 10) and treated orally with vehicle, or ORX (n = 40) and treated with either vehicle or lasofoxifene at 1, 10, or 100 μg/kg·day for 60 days. Total serum cholesterol, prostate weight and histol., distal femoral bone mineral d. (DFBMD) by dual energy x-ray absorptiometry, and static and dynamic bone histomorphometry of the third lumbar vertebral body were determined Maximal load and stiffness of the fifth lumbar vertebral body were also determined by compression tests. Age-related decreases in DFBMD (-9%) and trabecular bone volume (TBV; -13%) of the third lumbar vertebral body were found in sham-operated rats compared with basal controls. ORX induced significant increases in total serum cholesterol (+31%), eroded surface (+48%), activation frequency of bone turnover (+103%) and significant decreases in prostate weight (-89%), DFBMD (-14%), TBV (-23%), and maximal load (-17%) compared with basal controls. Compared with sham controls, ORX induced significant increases in eroded perimeter and activation frequency. Lasofoxifene decreased body weight in all dose groups compared with both sham and ORX control values. Compared with ORX controls, ORX rats treated with lasofoxifene at 10 or 100 μg/kg·day had significantly lower percent eroded perimeter activation frequency and significantly higher DFBMD, TBV, and maximal load. Further, lasofoxifene at 10 and 100 μg/kg·day significantly decreased total serum cholesterol by 46% and 68% in ORX rats, whereas no effect was found in prostate weight and histol. parameters compared with ORX control values. These data showed that lasofoxifene prevented bone loss by inhibiting bone turnover associated with aging and orchidectomy in 10-mo-old male rats. Further, lasofoxifene decreased total serum cholesterol and did not affect the prostate in these rats. These results suggest that SERMs such as lasofoxifene may be useful therapeutic agents for preventing bone loss in elderly men with some degree of hypogonadism.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 25 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:68983 HCAPLUS Full-text
DOCUMENT NUMBER: 132:102844
TITLE: Method of increasing testosterone with droloxifene or a related compound
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 5 pp., Cont. of U.S. Ser. No. 803,711, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6017964	A	20000125	US 1998-208729		19981209
PRIORITY APPLN. INFO.:			US 1996-21181P	P	19960228
			US 1997-803711	B1	19970221

GI



I

AB Methods are provided for increasing serum levels of testosterone which comprise administering to a mammal in need of such treatment an effective amount of I (R1 and R2 may be the same or different, provided that when R1 and R2 are the same, each is Me or Et, and when R1 and R2 are different, one is Me or Et and the other is H or benzyl) or a pharmaceutically acceptable salt thereof.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 26 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:818996 HCAPLUS Full-text
DOCUMENT NUMBER: 132:44985
TITLE: Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
INVENTOR(S): Ke, Hua Zhu; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 966968	A1	19991229	EP 1999-304374	19990604
EP 966968	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 265853	T	20040515	AT 1999-304374	19990604
PT 966968	T	20040831	PT 1999-304374	19990604
ES 2220005	T3	20041201	ES 1999-304374	19990604
CA 2274381	A1	19991216	CA 1999-2274381	19990614
CA 2274381	C	20040210		
JP 2000026298	A	20000125	JP 1999-167503	19990614
MX 9905564	A	20001130	MX 1999-5564	19990615
BR 9904146	A	20000509	BR 1999-4146	19990616
US 6284773	B1	20010904	US 1999-314371	19990714
PRIORITY APPLN. INFO.:			US 1998-89468P P	19980616

AB Combination compns. comprising (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol (I) or pharmaceutically acceptable salts and PGE2 or a pharmaceutically acceptable salt are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty. Expts. on rats show that I inhibits bone resorption and bone turnover, prevents further bone loss and preserves bone strength. Further I potentiates the bone restoration effects of PGE2 in established osteopenic rats.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 27 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:811078 HCAPLUS Full-text
DOCUMENT NUMBER: 132:45000
TITLE: Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty
INVENTOR(S): Ke, Hua Zhu; Li, Mei; Pan, Lydia Codetta; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9965488	A1	19991223	WO 1999-IB796		19990503
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2335112	A1	19991223	CA 1999-2335112		19990503
AU 9933420	A	20000105	AU 1999-33420		19990503
BR 9911357	A	20010313	BR 1999-11357		19990503
EP 1085867	A1	20010328	EP 1999-914723		19990503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
HU 200102395	A2	20011128	HU 2001-2395		19990503
JP 2002518328	T	20020625	JP 2000-554368		19990503
IN 1999DE00845	A	20050701	IN 1999-DE845		19990610
ZA 9903973	A	20001215	ZA 1999-3973		19990615
NO 2000006381	A	20001214	NO 2000-6381		20001214
HR 2000000857	A1	20011031	HR 2000-857		20001214
BG 105128	A	20011130	BG 2001-105128		20010108
PRIORITY APPLN. INFO.:			US 1998-89424P	P	19980616
			WO 1999-IB796	W	19990503

AB This invention is directed to pharmaceutical combination compns. and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)phenyl)- 5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(1(R)-(2,4-difluorobenzyloxymethyl)-2-oxo-2-(3-oxo- 3a(R)pyridin-2-ylmethyl)-2-(2,2,2-trifluoroethyl)-2,3,3a,4,6,7- hexahydropyrazolo[4,3-c]pyridin-5-yl)ethyl-2-methylpropionamide or a pharmaceutically acceptable salt thereof, methods of using such compns. and kits containing such compns. The compns. are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic combinations of estrogen receptor modulators and growth hormone secretagogues for treating musculoskeletal frailty)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 28 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:811077 HCAPLUS Full-text
DOCUMENT NUMBER: 132:44999
TITLE: Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty
INVENTOR(S): Ke, Hua Zhu; Li, Mei; Pan, Lydia Codetta; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965486	A1	19991223	WO 1999-IB1117	19990616
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9903975	A	20001215	ZA 1999-3975	19990615
CA 2335134	A1	19991223	CA 1999-2335134	19990616

AU 9940547	A1	20000105	AU 1999-40547	19990616
BR 9911324	A	20010403	BR 1999-11324	19990616
EP 1087764	A1	20010404	EP 1999-923802	19990616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200003544	T2	20010420	TR 2000-200003544	19990616
HU 200102505	A2	20011128	HU 2001-2505	19990616
JP 2002518326	T	20020625	JP 2000-554366	19990616
BG 105041	A	20010831	BG 2000-105041	20001211
NO 2000006312	A	20001212	NO 2000-6312	20001212
HR 2000000859	A1	20010430	HR 2000-859	20001214
PRIORITY APPLN. INFO.:			US 1998-89469P P	19980616
			WO 1999-IB1117 W	19990616

AB This invention is directed to pharmaceutical combination compns. and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)phenyl)- 5,6,7,8-tetrahydronaphtalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7- hexahydropyrazolo-[4,3-c]pyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo- ethyl)isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compns. and kits containing such compns. The compns. are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations of estrogen receptor modulators and growth hormone secretagogues for treating musculoskeletal frailty)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 29 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:811074 HCAPLUS Full-text
DOCUMENT NUMBER: 132:30842
TITLE: Therapeutic combinations comprising a selective

estrogen receptor modulator and parathyroid hormone
INVENTOR(S): Ke, Hua Zhu; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9965482	A1	19991223	WO 1999-IB949		19990526
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2335078	A1	19991223	CA 1999-2335078		19990526
AU 9937259	A1	20000105	AU 1999-37259		19990526
BR 9911228	A	20010213	BR 1999-11228		19990526
EP 1094808	A1	20010502	EP 1999-919491		19990526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
TR 200003567	T2	20010621	TR 2000-200003567		19990526
HU 200102759	A2	20020328	HU 2001-2759		19990526
JP 2002518323	T	20020625	JP 2000-554362		19990526
NZ 508039	A	20030328	NZ 1999-508039		19990526
ZA 9903972	A	20001215	ZA 1999-3972		19990615
US 6132774	A	20001017	US 1999-424010		19991115
NO 2000006313	A	20001212	NO 2000-6313		20001212
HR 2000000858	A1	20011031	HR 2000-858		20001214
BG 105125	A	20011130	BG 2001-105125		20010108
PRIORITY APPLN. INFO.:			US 1998-89479P	P	19980616
			WO 1999-IB949	W	19990526

AB This invention is directed to pharmaceutical combination compns. and methods comprising (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]- 5,6,7,8-tetrahydronaphthalen-2-ol (I) or a pharmaceutically acceptable salt thereof and parathyroid hormone (PTH) or a biol. active fragment thereof, methods of using such compns. and kits containing such compns. The compns. are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty. Data showed that combined treatment of PTH and I both restored bone mass and bone strength to established osteopenic, rats, and added extra cancellous bone to the proximal tibia and distal femur of the rats. I enhanced the bone restorative effects of PTH by a greated inhibition of bone resorption than bone formation.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations comprising selective estrogen receptor modulator and parathyroid hormone)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 30 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:212801 HCAPLUS Full-text
DOCUMENT NUMBER: 130:262143
TITLE: Method of treating Alzheimer's disease and other diseases and conditions with estrogen agonists and antagonists
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5889042	A	19990330	US 1997-803706	19970221

PRIORITY APPLN. INFO.: US 1997-803706 19970221
OTHER SOURCE(S): MARPAT 130:262143
GI



I

AB Compds. I [A = CH2, NR; B, D, E = CH, N; Y = (substituted) Ph, (substituted) naphthyl, (substituted) C3-8 cycloalkyl, etc.; J = CH2; Z1 = (CH2)pW(CH2)q, O(CH2)pW(CH2)q, etc.; G = NR7R8, heterocyclic ring; W = CH2, CH:CH, O, etc.; R = H, C1-6 alkyl; R7, R8 = H, Ph, C1-6 alkyl, etc.; n = 0-2; p, q = 0-3], and optical and geometric isomers and nontoxic pharmacol. acceptable acid addition salts, N-oxides, and quaternary ammonium salts thereof, are useful for treating or preventing Alzheimer's disease, premenstrual syndrome, peri-menopausal syndrome, a deficiency of thrombomodulin, uterine fibrosis, excessive myeloperoxidase activity, excessive thrombin, autoimmune disease, reperfusion damage of ischemic myocardium and insufficient testosterone. (-)-Cis-6-phenyl-5-[4-(2- pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol is claimed for inhibiting Alzheimer's disease.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists and antagonists for treatment of Alzheimer's disease and other diseases and conditions)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 31 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:56372 HCAPLUS Full-text
DOCUMENT NUMBER: 130:120020
TITLE: Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5861438	A	19990119	US 1997-803712	19970221

PRIORITY APPLN. INFO.: US 1997-803712 19970221
OTHER SOURCE(S): MARPAT 130:120020
GI



I

AB The present invention provides novel methods of inhibiting bone loss comprising administering to a mammal in need of such treatment an effective amount of a compound of formula (I) wherein R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a Me or Et group, and, when R1 and R2 are different, one of them is a Me or Et group and the other is a hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof; together with or in combination with parathyroid hormone. Pharmaceutical compns. containing compds. of the invention are claimed as is a kit containing a therapeutic amount of a compound of formula I and a pharmaceutical carrier in a first unit dosage form plus a therapeutic amount of a parathyroid hormone and a pharmaceutical carrier in a second unit dosage form.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 32 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:430074 HCAPLUS Full-text
DOCUMENT NUMBER: 129:100036
TITLE: Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5773477	A	19980630	US 1997-803707	19970221
PRIORITY APPLN. INFO.:			US 1997-803707	19970221
OTHER SOURCE(S):	MARPAT 129:100036			

GI



I

AB A novel method of treating or preventing osteoporosis in mammals comprises administering an effective amount of an estrogen agonist (I; R1, R2 =, Me, Et, PhCH2; when R1 = R2, each is Me or Et; when R1 ≠ R2, one is Me or Et and the other is H or PhCH2) or pharmaceutically acceptable salt thereof, together with a bone resorption-inhibiting polyphosphonate. Thus, tablets were prepared containing active ingredients 0.25-100, starch 45, microcryst. cellulose 35, PVP (as 10% aqueous solution) 4, Na CM-cellulose 4.5, Mg stearate 0.5, and talc 1 weight parts.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 33 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:202677 HCAPLUS Full-text
DOCUMENT NUMBER: 128:275095
TITLE: Pharmaceutical compositions containing dialkylaminoethoxyphenylhydroxyphenylphenyl butene for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733937	A	19980331	US 1997-804702	19970221
PRIORITY APPLN. INFO.:			US 1997-804702	19970221
OTHER SOURCE(S):	MARPAT 128:275095			

GI



I

AB Novel methods of inhibiting the symptoms of premenstrual syndrome comprising administering to a human in need of treatment an effective amount of a compound of formula I (R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a Me or Et group, and, when R1 and R2 are different, one of them is a Me or Et group and the other is hydrogen or a benzyl group), or a pharmaceutically acceptable salt thereof. A tablet contained active ingredient 0.25-100, starch 45, microcryst. cellulose 35, polyvinylpyrrolidone 4 (as 10% solution in water) sodium CM-cellulose 4.5, magnesium stearate 0.5, and talc 1 mg. Efficacy of 10-100 mg/day of the above drug by the oral route was studied for the inhibition of premenstrual syndrome and late luteal phase dysphoric disorder symptoms in women for a period of 1-3 mo.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 34 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:180551 HCAPLUS Full-text
DOCUMENT NUMBER: 128:248582
TITLE: Pharmaceutical composition for the protection of ischemic myocardium against reperfusion damage
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5726207	A	19980310	US 1997-805040	19970221

PRIORITY APPLN. INFO.: US 1997-805040 19970221
OTHER SOURCE(S): MARPAT 128:248582
GI



I

AB Novel methods of inhibiting reperfusion damage in ischemic myocardium comprise administering to a mammal in need of such treatment an effective amount of (I; R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a Me or Et group, and, when R1 and R2 are different, one of them is a Me or Et group and the other is hydrogen or a benzyl group); or a pharmaceutically acceptable salt thereof. Hard gelatin capsules were prepared containing I 0.25-100, starch 0-650, starch flowable powder 0-50, silicone fluid 350 cSt 0-15 mg/capsule.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 35 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:146573 HCAPLUS Full-text
DOCUMENT NUMBER: 128:184707
TITLE: Pharmaceutical compositions containing 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5719191	A	19980217	US 1997-805039	19970221

PRIORITY APPLN. INFO.: US 1997-805039 19970221
OTHER SOURCE(S): MARPAT 128:184707
GI



I

AB Novel methods of inhibiting Alzheimer's disease are provided comprising administering to a human in need of treatment an effective amount of a 1,1,2-triphenylbut-1-ene derivs. (I; R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a Me or Et group, and, when R1 and R2 are different, one of them is a Me or Et group and the other is hydrogen or a benzyl group) or a pharmaceutically acceptable salt thereof. A hard gelatin capsule contained I 0.25, starch 650, starch flowable powder 50, and silicone fluid 350 cSt 15 mg. Efficacy of compound of formula I in decreasing lactate dehydrogenase (a neurotoxic) release from cultured primary rat hippocampal neurons was shown.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 36 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:146572 HCAPLUS Full-text
DOCUMENT NUMBER: 128:196689
TITLE: Pharmaceutical compositions containing myeloperoxidase inhibitors
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5719190	A	19980217	US 1997-803709	19970221

PRIORITY APPLN. INFO.: US 1997-803709 19970221
OTHER SOURCE(S): MARPAT 128:196689
GI



I

AB Novel methods of inhibiting myeloperoxidase activity is provided comprising administering to a mammal in need of such treatment an effective amount of a compound I (R1, R2 may be the same or different provided that, when R1 and R2 are the same, each is a Me or Et, and when R1 and R2 are different, one of them is a Me or Et and the other is hydrogen or a benzyl) or a pharmaceutically acceptable salt thereof. A tablet contained active ingredient 100, starch 45, microcryst. cellulose 35, polyvinylpyrrolidone 4 (as 10% solution in water) sodium CM-cellulose 4.5, magnesium stearate 0.5, and talc 1 mg. Efficacy of I in treatment of women suffering from systemic lupus erythematosus and arthritis is shown.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 37 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:610807 HCAPLUS Full-text
DOCUMENT NUMBER: 127:253203
TITLE: Use of droloxifene for the manufacture of a medicament for increasing serum levels of testosterone
INVENTOR(S): MaClean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 793961	A1	19970910	EP 1997-301171	19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
IL 120262	A	20010128	IL 1997-120262	19970220
JP 09315962	A	19971209	JP 1997-39077	19970224
CA 2198535	A1	19970828	CA 1997-2198535	19970226
CA 2198535	C	20000620		
AU 9714966	A	19970904	AU 1997-14966	19970227
AU 712800	B2	19991118		
ZA 9701709	A	19980827	ZA 1997-1709	19970227
CN 1165649	A	19971126	CN 1997-103408	19970228
PRIORITY APPLN. INFO.:			US 1996-21181P P	19960228
OTHER SOURCE(S):	MARPAT 127:253203			

AB 3-[1-[4-(2-Aminoethoxy)phenyl]-2-phenyl-1-butenyl]phenol derivs., preferably droloxifene, are used for the manufacture of a medicament for increasing serum levels of testosterone. Formulations for capsules, tablets, suspensions,

aerosols, suppositories, and i.v. solns. are provided. Administration of droloxifene to men (62-75 yr old) at 10 and 40 mg per day significantly increased testosterone levels.

L18 ANSWER 38 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600540 HCAPLUS Full-text
DOCUMENT NUMBER: 127:243268
TITLE: Method of treating conditions with estrogen agonists
INVENTOR(S): Maclean, David Burton; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 792642	A1	19970903	EP 1997-301150	19970221
EP 792642	B1	20010822		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
TW 442286	B	20010623	TW 1997-86100636	19970121
IL 120267	A	20021110	IL 1997-120267	19970220
AT 204475	T	20010915	AT 1997-301150	19970221
ES 2159812	T3	20011016	ES 1997-301150	19970221
CA 2198562	A1	19970828	CA 1997-2198562	19970226
CA 2198562	C	20020910		
AU 9714980	A	19970904	AU 1997-14980	19970227
AU 703384	B2	19990325		
ZA 9701713	A	19980827	ZA 1997-1713	19970227
CN 1165655	A	19971126	CN 1997-103415	19970228
JP 10007564	A	19980113	JP 1997-45905	19970228
GR 3036874	T3	20020131	GR 2001-401737	20011011

PRIORITY APPLN. INFO.: US 1996-13213P P 19960228
OTHER SOURCE(S): MARPAT 127:243268

AB Estrogen agonists such as cis-6-(40fluorophenyl)5-[4-(2-piperidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol are used to treat pathol. condition such as Alzheimer's disease, premenstrual syndrome, premenopausal syndrome, a deficiency of thrombomodulin, uterine fibrosis, excessive myeloperoxidase activity, excessive thrombin, autoimmune disease, reperfusion damage of ischemic myocardium and insufficient testosterone.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists for treatment of pathol. conditions)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 39 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600513 HCAPLUS Full-text
DOCUMENT NUMBER: 127:253197
TITLE: Combination therapy to treat osteoporosis
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 792645	A1	19970903	EP 1997-301174	19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2198534	A1	19970828	CA 1997-2198534	19970226
AU 9714976	A	19970904	AU 1997-14976	19970227
CN 1165654	A	19971126	CN 1997-103409	19970228
JP 10007562	A	19980113	JP 1997-45060	19970228
CN 1178668	A	19980415	CN 1997-103412	19970228
PRIORITY APPLN. INFO.:			US 1996-13367P P	19960228
OTHER SOURCE(S):	MARPAT 127:253197			

AB A pharmaceutical composition comprising a compound such as cis-6-(4-fluorophenyl)- 5-[4-(2-piperidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol in combination with a bone resorption inhibiting polyphosphonate or a progestin is useful for treating or preventing osteoporosis.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonist in combination with polyphosphonate or progestin in treatment of osteoporosis)

RN 180916-16-9 HCAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 40 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600476 HCAPLUS Full-text
DOCUMENT NUMBER: 127:253196
TITLE: Use of (E)-1-(4-(2-alkylaminoethoxy)phenyl)-1-(3-hydroxyphenyl)-2-phenylbut-1-enes for inhibiting pathological conditions
INVENTOR(S): Maclean, David Burton; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 792640	A2	19970903	EP 1997-301149	19970221
EP 792640	A3	19980708		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5985932	A	19991116	US 1997-804346	19970221
CA 2198571	A1	19970828	CA 1997-2198571	19970226
AU 9714956	A	19970904	AU 1997-14956	19970226
AU 707455	B2	19990708		
ZA 9701710	A	19980827	ZA 1997-1710	19970227
CN 1165651	A	19971126	CN 1997-103416	19970228
JP 09328421	A	19971222	JP 1997-45616	19970228
PRIORITY APPLN. INFO.:			US 1996-12401P	P 19960228
			US 1996-12402P	P 19960228
			US 1996-12403P	P 19960228
			US 1996-12404P	P 19960228
			US 1996-12410P	P 19960228
			US 1996-12411P	P 19960228

OTHER SOURCE(S): MARPAT 127:253196
AB (E)-1-(4-(2-alkylaminoethoxy)phenyl)-1-(3-hydroxyphenyl)-2-phenylbut-1-enes are used for the manufacture of a medicament for inhibiting a condition selected from pathol. conditions related to organ systems which respond to

estrogen agonists, uterine fibrosis, myeloperoxidase activity, autoimmune diseases, reperfusion damage in ischemic myocardium, and the symptoms of premenstrual syndrome. An example compound is droloxifene and a number of pharmaceutical formulations were given.

L18 ANSWER 41 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600459 HCAPLUS Full-text
DOCUMENT NUMBER: 127:239138
TITLE: Combination therapy to treat osteoporosis or conditions which present low bone mass
INVENTOR(S): Maclean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 792639	A1	19970903	EP 1997-301148		19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CA 2198580	A1	19970828	CA 1997-2198580		19970226
CA 2198580	C	20010703			
AU 9714978	A	19970904	AU 1997-14978		19970227
AU 718242	B2	20000413			
ZA 9701711	A	19980827	ZA 1997-1711		19970227
CN 1166316	A	19971203	CN 1997-103406		19970228
JP 09328430	A	19971222	JP 1997-45288		19970228
US 6100301	A	20000808	US 1998-92100		19980605
PRIORITY APPLN. INFO.:			US 1996-12399P	P	19960228
			US 1996-12409P	P	19960228

OTHER SOURCE(S): MARPAT 127:239138
AB Aminoethoxyphenyl hydroxy Et stilbene derivs. together with a bone resorption inhibiting polyphosphonate or parathyroid hormone are useful for treating osteoporosis and that containing parathyroid hormone, for treating a condition which presents low bone mass. An example compound is droloxifene.

L18 ANSWER 42 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600450 HCAPLUS Full-text
DOCUMENT NUMBER: 127:243267
TITLE: Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 792641	A1	19970903	EP 1997-301147	19970221
EP 792641	B1	20010801		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
IL 120266	A	20050517	IL 1997-120266	19970220
US 6107331	A	20000822	US 1997-803733	19970221
EP 1106179	A2	20010613	EP 2001-101953	19970221
EP 1106179	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 203670	T	20010815	AT 1997-301147	19970221
ES 2159811	T3	20011016	ES 1997-301147	19970221
CA 2198578	A1	19970828	CA 1997-2198578	19970226
CA 2198578	C	20020611		
ZA 9701714	A	19970827	ZA 1997-1714	19970227
AU 9714979	A	19970904	AU 1997-14979	19970227
AU 703473	B2	19990325		
CN 1167617	A	19971217	CN 1997-103414	19970228
CN 1122513	B	20031001		
JP 10007563	A	19980113	JP 1997-45652	19970228
CN 1515256	A	20040728	CN 2003-2003141228	19970228
HK 1001963	A1	20040130	HK 1998-101068	19980212
US 6274618	B1	20010814	US 1999-314758	19990519
US 6355670	B1	20020312	US 2000-511806	20000223
US 2001018451	A1	20010830	US 2001-803516	20010309
US 6403611	B2	20020611		
GR 3036583	T3	20011231	GR 2001-401440	20010911
US 2002091121	A1	20020711	US 2001-999291	20011115
US 6613796	B2	20030902		
US 2003220349	A1	20031127	US 2002-133006	20020426
US 6911456	B2	20050628		
US 2004009994	A1	20040115	US 2003-615282	20030707
US 2005148625	A1	20050707	US 2005-71955	20050303
PRIORITY APPLN. INFO.:			US 1996-13212P	P 19960228
			EP 1997-301147	A3 19970221
			US 1997-803733	A1 19970221
			US 1999-314758	A1 19990519
			US 2000-511806	A3 20000223
			US 2001-803516	A3 20010309
			US 2001-999291	A3 20011115
			US 2002-133006	A3 20020426

OTHER SOURCE(S): MARPAT 127:243267

AB Estrogen antagonists or agonists such as cis-6-(4-fluorophenyl)-5-[4-(2-piperidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol are used to treat pathol. conditions such as breast disorder, vaginal atrophy, bladder infection, etc.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 43 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:600284 HCAPLUS Full-text
DOCUMENT NUMBER: 127:253172
TITLE: Use of 1,1,2-triphenylbut-1-ene derivatives for the manufacture of a medicament for treating Alzheimer's disease
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 792638	A1	19970903	EP 1997-301146	19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09315961	A	19971209	JP 1997-40458	19970225
CA 2198561	A1	19970828	CA 1997-2198561	19970226
AU 9714965	A	19970904	AU 1997-14965	19970227
ZA 9701716	A	19980827	ZA 1997-1716	19970227
CN 1165650	A	19971126	CN 1997-103410	19970228
PRIORITY APPLN. INFO.:			US 1996-25201 P	19960228

OTHER SOURCE(S): MARPAT 127:253172
AB Aminoethoxyphenyl(hydroxyphenyl)phenylbutene derivs. are used in the manufacture of a medicament for the treatment of Alzheimer's Disease. An example compound is droloxifene.

L18 ANSWER 44 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:594636 HCAPLUS Full-text
DOCUMENT NUMBER: 127:257642
TITLE: Combination therapy for osteoporosis with estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists
INVENTOR(S): Ke, Hua Zhu; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731640	A1	19970904	WO 1996-IB1462	19961223
W: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 464496	B	20011121	TW 1996-85115770	19961220
CA 2247420	A1	19970904	CA 1996-2247420	19961223
AU 9710398	A	19970916	AU 1997-10398	19961223
AU 703285	B2	19990325		
EP 883404	A1	19981216	EP 1996-941153	19961223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
CN 1209064	A	19990224	CN 1996-180058	19961223
JP 11504352	T	19990420	JP 1997-530738	19961223
BR 9612533	A	19990720	BR 1996-12533	19961223
HU 9904123	A2	20000528	HU 1999-4123	19961223
NZ 323456	A	20010330	NZ 1996-323456	19961223
TR 9801679	T2	20010621	TR 1998-1679	19961223
EP 1236475	A2	20020904	EP 2002-10920	19961223
EP 1236475	A3	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
RU 2190395	C2	20021010	RU 1998-117620	19961223
JP 2002308771	A	20021023	JP 2002-54756	19961223
PL 187219	B1	20040630	PL 1996-328831	19961223
CN 1515254	A	20040728	CN 2003-10120233	19961223
CN 1515316	A	20040728	CN 2003-10120234	19961223
CN 1515317	A	20040728	CN 2003-10120235	19961223
CN 1515258	A	20040728	CN 2003-10120236	19961223
PL 187962	B1	20041130	PL 1996-359987	19961223
CZ 297452	B6	20061213	CZ 1998-2718	19961223
ZA 9701719	A	19980827	ZA 1997-1719	19970227
AP 975	A	20010612	AP 2000-1962	19970227
W: BW, GM, KE, MW, UG, ZM, ZW				
AP 974	A	20010612	AP 1997-934	19970227
W: BW, GM, KE, MW, UG, ZM, ZW				
US 6323232	B1	20011127	US 1998-117972	19980811
BG 64582	B1	20050831	BG 1998-102726	19980826
NO 9803936	A	19980827	NO 1998-3936	19980827
HK 1018210	A1	20060728	HK 1999-103244	19990728
US 2001009920	A1	20010726	US 2000-736051	20001213
AP 1179	A	20030630	AP 2002-2661	20021107
W: BW, KE, MW, UG, ZM, ZW				
NO 2006003853	A	19980827	NO 2006-3853	20060829
PRIORITY APPLN. INFO.:			US 1996-12412P	P 19960228
			EP 1996-941153	A3 19961223
			JP 1997-530738	A3 19961223
			WO 1996-IB1462	W 19961223
			US 1998-117972	A3 19980811

OTHER SOURCE(S): MARPAT 127:257642

AB Pharmaceutical combination compns. are disclosed which include estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compns. are useful for the treatment of bone disorders including osteoporosis. The effects of PGE2 and droloxifene on bone mineral content and bone mineral d. in ovariectomized rats were determined The data support the strategy of using an anabolic agent to restore bone mass, followed by an anti-resorptive agent to maintain the restored bone mass.

IT 180916-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists as combination therapy for bone disorders including osteoporosis)

RN 180916-16-9 HCAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L18 ANSWER 45 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:589150 HCAPLUS Full-text

DOCUMENT NUMBER: 127:239133

TITLE: Pharmaceutical compositions containing combination of droloxifene and progestins for the treatment of osteoporosis

INVENTOR(S): Maclean, David B.; Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 791356	A1	19970827	EP 1997-301173	19970221

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

JP 09315977	A	19971209	JP 1997-39073	19970224
CA 2198574	A1	19970828	CA 1997-2198574	19970226
AU 9714967	A	19970904	AU 1997-14967	19970227
AU 712656	B2	19991111		
ZA 9701718	A	19980827	ZA 1997-1718	19970227
US 6057309	A	20000502	US 1998-193265	19981116
PRIORITY APPLN. INFO.:			US 1996-12400P	P 19960228
			US 1997-803710	B1 19970221

OTHER SOURCE(S): MARPAT 127:239133

AB Pharmaceutical compns. comprising an effective amount of droloxifene (Markush structure given) or a pharmaceutically acceptable salt thereof together with a progestin are useful for inhibiting bone loss. Tablets containing the above active ingredients 0.25-100, microcryst. cellulose 200-650, silicon dioxide 10-650, and stearic acid 5-15 mg each were prepared The efficacy of the combination in treatment of a model of post-menopausal osteoporosis in rats is shown.

L18 ANSWER 46 OF 46 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:402263 HCAPLUS Full-text
DOCUMENT NUMBER: 111:2263
TITLE: Metabolic activation of eugenol by myeloperoxidase in polymorphonuclear leukocytes
AUTHOR(S): Thompson, David; Constantin-Teodosiu, Despina; Norbeck, Kajsa; Svensson, Bjorn; Moldeus, Peter
CORPORATE SOURCE: Dep. Toxicol., Karolinska Inst., Stockholm, S-104 01, Swed.
SOURCE: Chemical Research in Toxicology (1989), 2(3), 186-92
CODEN: CRTOEC; ISSN: 0893-228X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The metabolism and adverse effects of eugenol (I) in human polymorphonuclear leukocytes (PMN) were studied. Myeloperoxidase, isolated and purified from human PMN, catalyzed the oxidation of I to a reactive intermediate which is likely to be a quinone methide. Eosinophil peroxidase, lactoperoxidase, prostaglandin H synthase, horseradish peroxidase, and rat intestinal peroxidase also supported this H2O2-dependent reaction. GSH inhibited the formation of this metabolite, resulting in the formation of glutathione disulfide and a small amount of I-GSH conjugates. In cellular incubations, phorbol ester stimulated PMN catalyzed the covalent binding of [3H]I to cellular protein, which was partially inhibitable by azide. Intracellular GSH levels decreased by 90% over a period of 30 min in phorbol ester-stimulated PMN exposed to 100 μM I compared with decreases of 30% (phorbol ester alone) or 5% (I alone) in control incubations. In addition, I was more cytotoxic to PMN in the presence of phorbol ester than in its absence, and I inhibited the phorbol ester stimulated oxidative burst in PMN as reflected by a decrease in O consumption, superoxide formation, and H2O2 formation. These results suggest that PMN are capable of activating I to a reactive intermediate and also suggest a mechanism whereby I can potentially interfere with and adversely affect vital PMN functions.

=>